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ABSTRAKT 
 
Univerzita Karlova v Praze 
Farmaceutická fakulta v Hradci Králové  
Katedra farmaceutické chemie a kontroly léčiv 
 
Kandidát: Klára Suchanová 
Školitel: doc. dr. Marko Anderluh, mag. farm.; PharmDr. Petr Zimčík, Ph.D.  
Název diplomové práce: Návrh a syntéza inhibitorů DDl založených 
na isothiazolidinonovém jádře 
 
Tato práce je zaměřená na D-Ala-D-Ala ligázu (DDl), enzym z alaninové boční 
cesty syntézy bakteriální buněčné stěny. Potenciální DDl inhibitory byly navrženy 
s pomocí dokovacího softwaru (AutoDock 4.05, The Scripps Research Institute, 
La Jolla, USA), rentgenových struktur DDl (1IOW a 1IOV, PDB), jejích přirozených 
substrátů/produktů a známých publikovaných inhibitorů. Tato práce je součástí projektu 
EUR-INTAFAR (Inhibition of New TArgets for Fighting Antibiotic Resistance), 
zaměřeného na lepší pochopení fyziologie a biochemie bakteriální buněčné stavby, 
biosyntézy peptidoglykanu a objevování nových antibakteriálních látek. Podle in silico 
návrhu bylo připraveno pět konečných produktů s isothiazolidinonovým jádrem a 
ohodnoceno v biologickém testování pro určení jejich DDl inhibičního účinku. 
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ABSTRACT 
 
Charles University in Prague  
Faculty of Pharmacy in Hradec Králové  
Department of Pharmaceutical Chemistry and Drug control 
 
Candidate: Klára Suchanová 
Supervisor: doc. dr. Marko Anderluh, mag. farm.; PharmDr. Petr Zimčík, Ph.D. 
Title of diploma thesis: Design and synthesis of isothiazolidinone-based DDl inhibitors 
 
This work is focused on D-Ala-D-Ala ligase (DDl), enzyme in alanine side 
pathway of the bacterial cell wall synthesis. Potential DDl inhibitors were designed 
with the help of docking software (AutoDock 4.05, The Scripps Research Institute, 
La Jolla, USA), X-ray structures of DDl (1IOW and 1IOV, PDB), its natural 
substrates/products and known published inhibitors. This work is a part of the project 
EUR-INTAFAR (Inhibition of New TArgets for Fighting Antibiotic Resistance) aiming 
at better understanding of the physiology and biochemistry of bacterial cell 
morphogenesis and peptidoglycan biosynthesis and the discovery of new antibacterial 
agents. According to the in silico design, five final compounds were synthesized 
with isothiazolidinone core and evaluated in the biological assays to determine their 
DDl inhibitory potency. 
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1. Introduction  
 
The development and introduction of antibiotics in the medical practice has 
drastically reduced illness and casulties from infectious diseases. However, bacteria 
exhibit a remarkable capacity to become resistant to commonly used antibacterial 
compounds. In parallel to efforts aimed at better understanding the strikingly diverse 
mechanisms they use, it is important to design strategies which will allow to counteract 
them and to search for new targets, ideally essential and specific to bacterial physiology 
(1). 
Our approach is based on the well-established facts that peptidoglycan 
biosynthesis and cell morphogenesis are related phenomena and that they are totally 
specific to bacterial cells, without even remotely equivalent processes in eukaryotic 
cells. By attempting to interfere with these processes by inhibiting enzyme activities or 
perturbing protein-protein interactions, we should be able to design new antibacterial 
compounds active against pathogenic organisms such as streptococci, staphylococci, 
enterococci or chlamydiae (1). 
Our goal, as a part of EUR-INTAFAR (Inhibition of New TArgets for Fighting 
Antibiotic Resistance) project, was the study, design and synthesis of potential 
inhibitors for the synthesis of soluble peptidoglycan precursors. Specifically we focused 
on D-Ala-D-Ala ligase (shortly DDl), an enzyme taking part in alanine side pathway of 
bacterial cell wall synthesis. 
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2. Theoretical part 
 
2.1. Antimicrobial resistance 
 
Microbes (the collective term for bacteria, fungi, parasites and viruses) cause 
infectious diseases, and antimicrobial agents, such as ampicillin, streptomycin and more 
than 150 others, have been developed to combat the spread and severity of many 
of these diseases. Resistance to antimicrobials is a natural biological phenomenon that 
can be amplified or accelerated by a variety of factors, including human practices. 
The use of an antimicrobial for any infection, real or feared, in any dose and over any 
time period, forces microbes to either adapt or die in a phenomenon known as "selective 
pressure". The microbes that adapt and survive carry genes for resistance, which can be 
passed on to next generation (2). 
Bacteria are particularly efficient at enhancing the resistance, not only because 
of their ability to multiply very rapidly but also because they can transfer their 
resistance genes, which are passed on not only when the bacteria replicate. Resistant 
bacteria can also pass on their resistance genes to other related bacteria through 
"conjugation", whereby plasmids carrying the genes that “jumpˮ from one organism 
to another. Resistance to a single drug can thus spread rapidly through a bacterial 
population. When antimicrobials are used incorrectly - for too short a time, at too low 
dose, at inadequate potency; or for the wrong disease - the likelihood that bacteria and 
other microbes will adapt and replicate rather than be killed is greatly enhanced (2, 3). 
Several mechanisms have evolved in bacteria which confer them with antibiotic 
resistance. In general, there are 4 major strategies to achieve antibiotic resistance. 
1) Drug inactivation: by production of β-lactamase (penicillinase) and other enzymes 
to hydrolyze the antibiotics.  
2) Altered uptake: in Gram-negative bacteria the antibiotics diffuse through porins 
in the outer membrane and changes in the porin channel may lead to a decrease 
of the influx of antibiotics. Although some bacteria actively export antibiotics by 
multifunctional transporters, most antibiotics active in prevention of peptidoglycan 
biosynthesis are not required to enter the cytoplasm. Exceptions are D-cycloserin and 
phosphomycin acting in cytoplasm.  
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3) Altered target site: the resistance to penicillins commonly involves changes 
in penicillin-binding proteins and resistance to vancomycin may be the result 
of a change in the peptide attached to N-acetylmuramic acid (NAM).  
4) Metabolic bypass of inhibited reaction or overproduction of antibiotic target 
(titration): this strategy is used frequently in bacteria for combating trimethoprim and 
sulfonamides effect (3, 4). 
To combat the occurrence of resistant bacteria, the search for new antibiotic 
must not stop. Biotechnology and pharmaceutical companies and academic institutions 
must constantly search for, develop and test new antimicrobials in order to maintain 
a pool of effective drugs on the market. Previously, new drugs were discovered 
exclusively in bacterial whole cell growth assays. Today’s more rational approach 
depends on the identification of suitable target genes and proteins. These should be 
bacteria-specific and essential for growth either in vitro or in vivo (5). 
Targets within cell wall synthesis and remodelling pathways are particularly 
attractive because the bacterial cell wall is a unique structure occurring only 
in prokaryotes. Its main constituent, the peptidoglycan, is already the target of two 
major therapeutic classes in our current arsenal, namely the β-lactams and 
the glycopeptides, which inhibit the late stages of its biosynthetic pathway. Acquisition 
of resistance to these two classes of antibiotics has revealed the high flexibility in this 
assembly pathway and the need to target other enzymes acting on earlier steps. Among 
them, D-alanyl-D-alanine ligases are of particular interest because they use substrates 
(D-amino acids) that are specific for the bacteria and are essential for bacterial growth 
(5, 6). 
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2.2.  Bacteria and their cell wall  
 
Bacteria are unicellular microorganisms having a variety of characteristics 
allowing their classification. One major classification scheme is based upon their 
staining properties using the "Gram stain" procedure. In this procedure, heat-fixed 
bacteria are exposed to the purple dye crystal violet and iodine. This combination forms 
a dye complex in the bacterial cell wall. Treatment of the stained bacteria 
with a decolorizer like ethanol will wash away the dye complex from some bacteria but 
not others. Bacteria that retain the crystal violet-iodine complex appear purple and are 
called "Gram-positive". Bacteria that lose the dye complex can be counterstained 
with the red dye saffranin so that they appear red. These bacteria are called "Gram-
negative". The basis of the Gram reaction lies within the structure of the cell wall, 
described below (3). 
Figure 1: Structure 
of the Gram-positive 
bacterial cell wall (7). 
The wall is relatively 
thick and consists of many 
layers of peptidoglycan 
interspersed with teichoic 
acids that run 
perpendicular to 
the peptidoglycan sheets.  
 
 
The cell walls of Gram-positive bacteria (see Figure 1) are quite thick 
(20-80 nm) and consist of between 60 % and 80 % peptidoglycan, which is extensively 
cross-linked in three dimensions to form a thick polymeric mesh. Gram-positive walls 
frequently contain acidic polysaccharides called teichoic acids, these are either ribitol 
phosphate or glycerol phosphate molecules that are connected by phosphodiester 
bridges. Because they are negatively charged, teichoic acids are partially responsible 
for the negative charge of the cell surface as a whole. Their function may be to effect 
passage of metal cations through the cell wall. In some Gram-positive bacteria 
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glycerol-teichoic acids are bound to membrane lipids and are termed lipoteichoic acids. 
Cell wall proteins, if present, are generally found on the outer surface 
of the peptidoglycan (3, 8). 
The wall, or more correctly, envelope of Gram-negative cells (see Figure 2) is 
far more complicated structure. Although they contain less peptidoglycan (10-20 % 
of wall), a second membrane structure is found outside the peptidoglycan layer. This 
outer membrane is asymmetrical, composed of proteins, lipoproteins, phospholipids and 
a component unique to Gram-negative bacteria,  lipopolysaccharide (LPS). Essentially, 
the outer membrane is attached to the peptidoglycan by a lipoprotein, one end of which 
is covalently attached to peptidoglycan and the other end is embedded in the outer 
membrane. The outer membrane is not a phospholipid bilayer although it does contain 
phospholipids in the inner leaf, and its outer layer is composed of LPS, 
a polysaccharide-lipid molecule. Proteins are also found in the outer membrane, some 
of which form trimers and traverse the whole membrane and in so doing form 
water-filled channels or porins through which small molecules can pass. They are 
thought to act as a mechanism of selectivity for the ingress or exclusion of metabolites 
and antibacterial agents. Other proteins that mediate export of proteins or function 
as bacteriophage receptor and specific uptake channel are part of the outer membrane 
(3, 8). 
Figure 2: Structure of 
the Gram negative cell wall 
(7). The wall is relatively 
thin and contains much less 
peptidoglycan than the 
Gram-positive wall. Also, 
teichoic acids are absent. 
However, the Gram-negative 
cell wall consists of an outer 
membrane that is outside 
of the peptidoglycan layer. 
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2.3. Peptidoglycan, its structure and synthesis 
 
Peptidoglycan (or murein) is a continuous covalent macromolecular structure 
found exclusively on the outside of the cytoplasmic membrane of almost all eubacteria. 
Its main function is to preserve cell integrity by withstanding high osmotic pressure. 
Peptidoglycan is also responsible for the maintenance of a defined cell shape, and it is 
intimately involved in cell growth and cell division. Its absence from cells will lead to 
their swelling in a hypotonic medium and to the rupture of the cytoplasmic membrane. 
For this reason, peptidoglycan is a validated target for almost all clinically useful 
antibiotics that inhibit bacterial cell-wall synthesis. Peptidoglycan also regulates 
the diffusion of molecules into cells, participates in the regulation of cell division and is 
an anchoring structure for cell-wall teichoic acid, proteins and polysaccharides, which 
are covalently linked to peptidoglycan. Bacteria often release peptidoglycan fragments, 
which function as signals in cell–cell communication (9, 10).  
The main structural features of this giant macromolecule are linear glycan chains 
interlinked by short peptides (see Figure 3). The glycan chains are composed of 
alternating units of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc), all linkages between sugars being β,1-4. The carboxy group of each 
N-acetylmuramic acid residue is connected to a peptide subunit, which is most often 
L-alanyl-γ-D-glutamyldiaminopimelyl-(or L-lysyl)-D-alanyl-D-alanine in nascent 
peptidoglycan monomer precursor, and which subsequently loses one or both D-alanine 
residues during mature peptidoglycan biosynthesis. Neighboring glycan chains are 
interlinked either by a direct peptide linkage between D-Ala at position 4 of one peptide 
subunit and the amino group of the diaminoacid at position 3 of other peptide subunit. 
Alternatively, glycan chains may be connected by a short peptide bridge between two 
peptide subunits between the carboxyl group of D-Ala at position 4 and the amino 
group of the diaminoacid at position 3. (9, 11).  
The structure of the glycan chain of peptidoglycan is conserved in all bacteria, 
with only minor variations, such as a different extent of O-acetylation. This provides 
resistance against lysozyme, a peptidoglycan-lytic enzyme. By contrast, 
the composition of the peptide varies substantially: Gram-negative bacteria and 
Gram-positive bacilli have meso-diaminopimelic acid (DAP) as the third amino acid 
(DAP-type peptidoglycan), whereas most other Gram-positive bacteria (including 
SUCHANOVÁ KLÁRA                                                                                     DIPLOMOVÁ PRÁCE    
13 
Gram-positive cocci) have L-lysine as the third amino acid (Lys-type peptidoglycan). 
The DAP-type peptides are usually directly crosslinked, and the Lys-type peptides are 
usually crosslinked through an interpeptide bridge that varies in length and amino-acid 
composition in different bacteria (e.g. -(Gly)5- pentaglycine bridge in S. aureus 
peptidoglycan) (10, 12). 
 
Figure 3: Scheme of the primary structure of bacterial peptidoglycan (9). 
Abbreviations: GlcNAc: N-acetylglucosamine; MurNAc: N-acetylmuramic acid; DA: 
diamino acid (generally diaminopimelic acid or L-lysine); n: number of amino acids 
in the cross-bridge (n = 0 to 5 depending on the organism). D-Ala: often missing 
in the peptidoglycan of many organisms. 
The biosynthesis of bacterial cell wall peptidoglycan is a complex process that 
has been investigated in
 
various organisms and an overall view valid for both 
Gram-positive
 
and Gram-negative bacteria has emerged. It can be divided into 3 
successive stages each of which consists of a series of reactions occurring at different 
locations in the bacteria, namely in the cytoplasm (synthesis of the nucleotide 
precursors), on the inner side (synthesis of lipid-linked intermediates) and outer side 
(polymerisation reaction) (13, 14). 
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The cytoplasmatic stage (see Figure 4) leads to the formation of an activated 
form of a monomeric glycopepentapeptidic unit (UDP-MurNAc-pentapeptide). It can be 
divided into 4 sets of reactions. The 1
st
 set leads to a formation 
of UDP-N-acetylglucosamine from fructose-6-phosphate (mediated by GlmS, GlmM, 
GlmU enzymes), 2
nd
 one leads to the synthesis UDP-N-acetylmuramic acid from 
UDP-N-acetylglucosamine (mediated by MurA and MurB enzymes), 3
rd
 
to UDP-N-acetylmuramyl pentapeptide from UDP-N-acetylmuramic acid (mediated by 
MurC, MurD, MurE and MurF enzymes) and the 4
th
 set are side pathways of synthesis 
of D-glutamic acid and dipeptide D-alanyl-D-alanine (mediated by MurI, Alr and DDl). 
The closer look on D-Ala-D-Ala formation (the part of peptidoglycan biosynthesis we 
are interested in the most), DDl enzyme and its inhibitors is taken in following chapters 
(13). 
Figure 4: Stepwise assembly of the peptidoglycan monomer unit (9). 
 
Finished peptidoglycan is an insoluble polymer outside the cytoplasmic 
membrane. The water-soluble precursors created in first stage must therefore cross 
the membrane. To do this, a carrier lipid is employed. This step is usually called second 
stage of peptidoglycan synthesis (see also Figure 4) and it takes place on inner side 
of cytoplasmatic membrane. It starts with the attachment of the MurNAc-pentapeptide 
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to a lipid carrier (undecaprenoyl phosphate) at the inner face of the membrane. 
The reaction is catalyzed by transferase MraY and
 
yields lipid I. The addition 
of GlcNAc to lipid I by transferase
 
MurG leads to lipid II, which carries the complete 
disaccharide
 
peptide monomer unit: GlcNAc-MurNAc-L-Ala-γ-D-Glu-A2pm(or L-Lys)-
D-Ala-D-Ala. In the course of the formation of the lipid intermediates the
 
peptide 
subunit can undergo various modifications (e.g. amidation of the α-COOH group of Glu 
and attachment of the (Gly)5 bridge to the ε-NH2 group of Lys in S. aureus). The final 
lipid intermediate
 
is transfered by a not thoroughly known mechanism (supposedly 
some specific translocase or flippase) through the hydrophobic
 
environment 
of the membrane to the externally located sites
 
of incorporation of the monomer unit 
into growing peptidoglycan (9, 12, 15). 
 
Figure 5: General scheme of peptidoglycan biosynthesis divided into 3 stages (16). 
 
The third and last stage (see Figure 5) of peptidoglycan synthesis concerns 
the polymerization
 
of the monomer unit on the outside surface of the cytoplasmic
 
membrane and the binding of newly made monomer unit to the preexisting
 
cell wall. 
Two major types of membrane-bound activities
 
are involved: transglycosylation 
mediated by glycosyltransferases that catalyze the formation
 
of linear glycan chains 
from single disaccharide peptide units, new β-(1→4) glycosidic bonds are formed. And 
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transpeptidation mediated by transpeptidases that catalyze
 
the formation of the peptide 
cross-bridges, directly (Gram-negative bacteria) or via a peptide bridge (S. aureus) (14). 
During this process the new peptidoglycan is detached from the lipid carrier, 
which is released as undecaprenyl pyrophosphate. The pyrophosphate loses one 
phosphate and the undecaprenyl phosphate is recycled. This process is inhibited by 
bacitracin which complexes with the P-P. The polymeration reactions are inhibited by 
glycopeptides and β-lactams. Vancomycin forms tight H-bonding to the terminal D-Ala-
D-Ala, whereas β-lactam antibiotics bind covalently to transpeptidases, hence these 
enzymes are called penicillin-binding proteins (12, 14). 
The process of cross-linkage of peptide chains produce the insoluble, strong 
mesh of peptidoglycan. It involves enzyme-catalysed attack by a free NH2 group 
of terminal Gly from pentaglycine bridge (S. aureus) or DAP (E. coli) on the C=O 
of the penultimate D-Ala, breaking the peptide bond and releasing the 'surplus' D-Ala. 
In growing cells,
 
polymerization reactions are accompanied by concomitant or 
subsequent
 
structural modifications of peptidoglycan (12, 14). 
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2.4. Side pathway – Formation of D-Ala-D-Ala 
 
D-Ala-D-Ala dipeptide is essentially found in peptidoglycan. It is produced from 
L-Ala through the action of two enzymes, alanine racemase (Alr, EC 5.1.1.1) and 
D-alanine-D-alanine ligase (DDl, EC 6.3.2.4) (17). 
D-Ala-D-Ala formation takes place in the cytoplasm during the first stage of the 
peptidoglycan synthesis pathway. Reaction catalysed by Alr is a racemization of 
L-alanine, Alr requires pyridoxal 5´-phosphate as a cofactor. The Alr reaction proceeds 
via a two-base mechanism through a planar carbanionic intermediate (see Figure 6). 
The reaction is reversible (13, 18). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Alanin racemase catalysed reaction mechanism (18). Lys39 and 
Tyr265´act as the catalytic bases abstracting the α-hydrogen from D-Ala and L-Ala, 
respectively. The reaction proceeds through a planar carbanionic intermediate. 
 
The second reaction in D-Ala-D-Ala formation is a condensation of two 
molecules of D-alanine which were previously formed by Alr. It is catalysed by 
an ATP-dependent DDl enzyme. Detailed kinetic and specificity studies provided 
evidence for two D-alanine-binding sites which have different specificity patterns and 
Michaelis constants. The binding site for the N-terminal D-Ala, designated as the donor 
site, is highly specific for D-Ala whereas the C-terminal D-Ala binding site, 
the acceptor site, is less specific and accepts a variety of D-amino acids. The reaction 
(see Figure 7) consists in a two-step process, the first step concerns the rapid transfer of 
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the γ-phosphate of ATP to the first D-alanine (D-Ala1) leading to an acetylphosphate 
product (D-alanyl-phosphate), in the second step follows the nucleophilic attack 
on the D-alanylphosphate by the amino group of the second substrate (D-Ala2) 
producing a tetrahedral intermediate. The latter is then dissociated to generate 
the product of the reaction (D-alanyl-D-alanine) and a phosphate group. The reaction is 
reversible. Ligase activity is strongly inhibited by its reaction product D-alanyl-
D-alanine. This tight regulation of the D-alanyl-D-alanine pool appears to be a 
physiological requirement to avoid depletion of the L-alanine pool (9, 13, 19). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Mechanism of the D-Ala-D-Ala ligase reaction (19). Phosphorylation 
of the carboxyl donor is followed by nucleophilic attack by the amino donor to give 
a tetrahedral adduct. Tautomerization by proton transfer leads to an intermediate that 
loses inorganic phosphate (Pi) and forms the D-Ala-D-Ala dipeptide. 
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2.5. D-Ala-D-Ala ligase 
 
D-Alanine-D-alanine ligase (EC 6.3.2.4) is an enzyme which belongs to family 
of ligases, specifically those forming carbon-nitrogen bonds, and to subfamily 
of acid-amino-acid ligases (peptide synthases). Enzymes from this subfamily possess 
ATP-dependent carboxylate-amine ligase activity and their catalytic mechanisms are 
likely to include acylphosphate intermediates (17, 20). 
The systematic name of this enzyme class is D-alanine:D-alanine ligase 
(ADP-forming). Other names in common use include MurE synthetase (ambiguous), 
alanine:alanine ligase (ADP-forming) and alanylalanine synthetase. This enzyme 
participates in D-alanine metabolism and peptidoglycan biosynthesis. 
In the biosynthesis of the peptidoglycan component of the bacterial cell wall DDl 
catalyses the following reaction:  
ATP  +  2 D-alanine  →  ADP  +  Pi  +  D-analyl-D-alanine 
 
The ligase was first detected in the early 1960s in Gram-negative as well as 
Gram-positive bacteria and soon afterwards it was partially purified from Enterococcus 
faecalis (formerly Streptococcus faecalis) (21). The gene for the E. coli DDl enzyme 
has been cloned and sequenced by Robinson et al. (1986) (22) and, not unexpectedly, 
this gene was shown to be essential for the growth of the organism (23). 
No long after, two distinct genes encoding D-Ala-D-Ala ligase activity in E. coli 
have been revealed, namely ddlB and ddlA (24). Even different kinds of DD-ligases 
in various bacteria were discovered when the vancomycine resistance was studied. 
Some of them are producing D-alanyl-D-serine dipeptide or a D-alanyl-D-lactate 
depsipeptide instead of D-alanyl-D-alanine.  
Replacing the terminal D-alanine by a D-serine or a D-lactate is responsible 
for vancomycin resistance described in Enterococcus species (VRE: Vancomycin 
Resistant Enterococci) and more recently in a vancomycin-resistant Staphylococcus 
aureus (VRSA). Decrease of vancomycin affinity for the corresponding peptidoglycan 
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termini is due to conformational change with D-alanyl-D-serine and to the loss of one 
hydrogen bond with D-alanyl-D-lactate (6). 
Homology analysis of the D-Ala-D-X (where X = alanine, serine or lactate) 
superfamily of bacterial ligases revealed five constituent families: two that are 
D-Ala-D-Ala ligases physiologically, two that are D-Ala-D-Lac ligases and one 
D-Ala-D-Ser ligase family (see Figure 8) (25, 26). 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Phylogenetic tree of D-Ala–D-X ligase superfamily (25). 
Syn, Synechocystis sp.; Bsu, Bacillus subtilis; Enterococci, Enterococcus sp. (Enterococcus faecalis); 
Streptococci, Streptococcus sp. (Streptococcus pneumonia); Sco, Streptomyces coelicolor; Msm, 
Mycobacterium smegmatis; Mtu, Mycobacterium tuberculosis; Bbu, Borrelia burgdoferi; Hpy, 
Helicobacter pylori; Bap, Buchnera aphidicola; Hin, Haemophilus influenzae; EcoB, E. coli (ddlB); Rpr, 
Rickettsia prowazekii; Aae, Aquifex aeolicus; Sto, Streptomyces toyocaensis (ddlM ); Aor, Amycolatopsis 
orientalis (ddlN); BpoE, Bacillus popilliae (vanE); OtuA2, Oerskovia turbata (vanA2); EfsA, 
Enterococcus faecium (vanA); EfmB2, Enterococcus faecium (vanB2); EfsB2, Enterococcus faecalis 
(vanB2); SboB2, Streptococcus bovis (vanB2); EfmB, Enteroccus faecium (vanB); Ega, Enterococcus 
gallinerum (vanC); Eca, Enterococcus casseliflavus (vanC2); Efl, Enterococcus flavescens (vanC3); Lme, 
Leuconostoc mesenteroides; Wco, Weassella confusa; Lpl, Lactobacillus plantarum; Lsa, Lactobacillus 
salivarius; EcoA, E. coli (ddlA); Sty, Salmonella typhimurium. Stars refer to alignments based on partial 
sequences. 
 
Several crystal structures have been solved for DDl enzymes. Their examination 
showed that at the quaternary structure level, two DDl monomers are forming a dimer 
(27). 
At the tertiary structure of D-alanine-D-alanine ligase, the enzyme is made of 
three domains, N-terminal, central and C-terminal domain, each consisting of a β-sheet 
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core surrounded by helices and loops (see Figure 9). Sandwiched between the sheets 
of the C-terminal and central domains is an ADP-binding site, the phosphinate binding 
site (which corresponds to binding site of D-alanines in tetrahedral intermediate state) is 
accommodated between the central and N-terminal domains (27, 28). 
Other important nonregular secondary structures of DDl are three loops covering 
the ligand binding site. One of them is called ω-loop. This loop of the enzyme exhibit 
a required flexibility that allows entry of ATP and substrates, provides protection 
of the acylphosphate intermediate and tetrahedral transition state from hydrolysis during 
catalysis, and then permits release of products (27, 28, 29). 
Figure 9: DDlB of E. Coli with ADP and methylphosphinophosphate inhibitor 
(1IOV pdb processed in Chem3D program). 
 
In the region of the active site of DDl it is possible to identify residues 
establishing strong interactions with ADP or the methylphosphinophosphate inhibitor. 
These residues in the E. coli DDl structure are shown in Figure 10. The adenine ring of 
the nucleotide lies in a pocket mainly composed of hydrophobic and aromatic residues. 
The ribose, α- and β-phosphate groups as well as the two Mg2+ ions interact with three 
lysines, which form electrostatic links with the phosphate groups of ADP. The two 
Mg
2+
 ions, which are essential for phosphate transfer and bridge ADP and the inhibitor 
phosphate group, interact with Glu, Asn and Asp residues. The ammonium group of the 
inhibitor interacts with two glutamic acids and one serine. The carboxylic group is 
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maintained at the other end of the inhibitor by one hydrogen bond to a serine side chain 
and one hydrogen bond to a residue main chain. In the center of the inhibitor, the P=O 
oxygen interacts with Arg225 and Gly276 side chains. The phosphate group of 
the phosphorylated inhibitor interacts with a lysine215 residue. The two side chains of 
the inhibitor make contacts with hydrophobic groups, the CH2 group in the inhibitor that 
corresponds to the NH group of the second D-alanine or the OH group of the lactate 
substrate interacts with an aromatic residue Tyr216. Residue Tyr216 located on omega 
loop is important not only for activity in substrate positioning but also for its substrate 
specificity. Its replacement by Phe converts the dipeptide ligase to an enzyme that has 
depsipeptide ligase activity (6, 25, 27). 
 
Figure 10: DDl active sites environment (6). Residues interacting with ADP and the 
two magnesium ions (A - hydrophobic and aromatic, B - polar and charged residues), C 
- residues interacting with the methylphosphinophosphate inhibitor. 
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2.6.  DDl inhibitors 
 
Over the last 50 years, 4 main categories of inhibitors of the DDl have been 
described - analogues of the substrate, analogues of the product, analogues 
of the transition state (see Fig. 11) and other inhibitors. 
 
Figure 11: Mechanism of the D-Ala-D-Ala ligase reaction (6). 
 
They have different capacity of inhibiting the enzyme in vitro, but some of them 
also prevent bacterial growth. In the absence of a transport system, this second property 
implies that the molecules are sufficiently amphiphilic to cross the bacterial membrane 
and reach the DDl in the cytosol. Yet, they must remain capable of interacting 
with an enzyme characterized by a highly hydrophilic catalytic cavity. Some bacteria 
(like E. coli) also produce two ligases (DDlA and DDlB), which may not be equally 
susceptible to a given inhibitor (6). 
 
Analogues of the substrate 
 
D-cycloserine (Figure 12/B) (D-4-amino-3-isoxazolidone), the first inhibitor 
of DDl ever described in the literature, is a cyclic structural analogue of D-alanine 
(Figure 12/A), produced by cultures of Streptomyces garyphalus and Streptomyces 
lavendulae, though drug material is prepared synthetically. Across the cell wall is 
transported via the alanine/glycine transport system. Cycloserine is water soluble and 
has a broad spectrum of antibacterial activity, but it is used only against Mycobacterium 
tuberculosis for the treatment of tuberculosis and only in combined therapies because 
of a bacteriostatic activity, the frequent development of resistance and its serious side 
effects, mainly neurotoxicity. Cycloserine behaves like structural analogue 
of D-alanine, inhibiting the incorporation of D-alanine into bacterial cell wall by 
inhibition of DDl. Cycloserine has high affinity for both D-alanine binding sites, 
inhibition is competitive and completely reversible with Ki = 0.25mM. It is also 
inhibitor of alanine racemase enzyme (30, 31). 
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A                                  
       
 
 
B                  C 
                                   R = H                  D-cycloserine        
                                 R = cis-CH3        cis-D-cyclothreonine 
                              R = trans-CH3    trans-D-cyclothreonine    
 
 
D          E          F                                        
 
R1 = H    R2 = H     D-Ala(P) 
                                   R1 = H    R2 = Cl    Cl-Ala(P) 
R1 = Cl   R2 = Cl    Cl2-Ala(P)   
 
Figure 12: DDl inhibitors, analogues of the substrate. A) D-Alanine - the template, 
B) D-Cycloserine and derivatives, C) Ala-B, D) Ala-P and derivatives, 
E) DL-(1-Amino-2-propenyl)phosphonic acid, F) 1-(aminoethyl)phosphinic acid 
 
There are also studies with D-cycloserine analogues (Figure 12/B), 
cis-D-cyclothreonine and trans-D-cyclothreonine to find out how changes into skelet 
influence the inhibitory effect. cis-D-Cyclothreonine proved better (Ki = 0.12 mM) and 
trans-D-cyclothreonine worse (Ki = 0.54 mM) inhibitory effect than D-cycloserine (6). 
Another DDl inhibitor was discovered at Harvard Medical School in Boston. 
There was synthetised boronic acid derivative, D-alanine analogue, 
(1-aminoethyl)boronic acid (Ala-B) (Figure 12/C) in which a boronic acid group 
replaces the carboxyl group. Ala-B also inhibits alanine racemase. Kinetic analysis 
suggests that Ala-B competes with D-alanine at D-alanine binding sites. Ala-B creates 
with DDl and alanine racemase long-living, slowly dissociating complexes with Ki = 
35 μM (32). 
In laboratories in Paris and Bordeaux was synthetised and for DDl inhibition 
tested another group of D-Alanine analogues, namely D-(α-aminoethyl)-phosphonic 
acid (Ala-P) and β-chloro-, β,β-dichloro and β,β,β-trichloro derivatives of Ala-P 
(Figure 12/D). They inhibit DDl and also alanine racemase. The Ki values 
of aforementioned compounds are satisfactory (e.g. Ki of Ala-P = 0.5 mM), but only 
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poor antibacterial activity was observed, most probably because they are unable to gain 
access to their cytoplasmic target due to their highly polar character (33). 
Another developped inhibitor of DDl is DL-(1-amino-2-propenyl)phosphonic 
acid (Figure 12/E) , analogue of vinylglycine with Ki = 5 mM. It is also strong inhibitor 
of alanine racemase, though its molecule is ineffective against whole bacterial cells. 
Also 1-(aminoethyl)phosphinic acid (Figure 12/F), a phosphinic analogue 
of Ala(P) is DDl inhibitor with Ki = 0.4 mM. This compound was synthesized in order 
to analyze the effect of the oxidation state of the phosphorus atom on the inhibition. 
Phosphinic group show a behavior closer to carboxyl group compared 
to the phosphonate group (6). 
 
Analogues of the product  
 
    R1 = CH3  R2 = CH3   D-Ala-D-Ala 
      R2 = CH2CH3  D-Ala-D-butyr 
      R2 = (CH2)2CH3 D-Ala-D-norval 
      R2 = CH2OH  D-Ala-D-Ser 
      R2 = CH2(CH3)OH D-Ala-D-Thr 
 
Figure 13: DDl inhibitors, analogues of the product.  
 
DDl is inhibited by its own product, D-Ala-D-Ala dipeptide (Ki = 1.2 mM). 
Product inhibition is a common feature among enzymes. In one study, D-Ala was 
incubated with either D-serine, D-threonine, D-norvaline or D-aminobutyric acid 
in the presence of DDl, the corresponding mixed dipeptide is formed in addition 
to D-Ala-D-Ala. These dipeptides (Figure 13) produce inhibition and several of these 
mixed peptides are slightly more effective inhibitors than D-alanyl-D-alanine itself 
(i.e. D-Ala-D-Ser, Ki = 0.91mM, D-Ala-D-norval, Ki = 0.55mM). Specific inhibition 
was observed only for dipeptides with the DD configuration. Also L-Ala-L-Ala had no 
inhibition effect on the DDl enzyme (21, 34). 
 
Analogues of the transition state 
 
Several (3-amino-2-oxoalkyl)phosphonic acids have been synthetised in Merck 
Institute laboratories as possible inhibitory dipeptide mimetics of D-alanyl phosphate 
(see  Figure 14/A), intermediate of D-Ala-D-Ala synthesis. Of them, the most active 
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NH
OH
O
OR1
R2
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of them 3-(R)-amino-2-oxobutylphosphonic acid (Ki = 510 μM) and the corresponding 
aza analogue (Ki = 50 μM) (see Figure 14/B) are effective DDl inhibitors although they 
have no significant antibacterial activity. The aza analogue is a better inhibitor than 
the methylene analogue since the polarity and bond length of the NH-P group mimics 
better the P-O bond of the activated complex D-alanyl phosphate formed in the acceptor 
site. E-3-Aminobutenylphosphonic acid (see Figure 14/B) is a good competitive 
inhibitor of D-alanyl-D-alanine ligase, with a Ki value close to 1 μM. However, this 
highly polar compound did not show any significant antibacterial activity (35). 
A.              B.     Y = CH2  
Y = NH 
Y = (E)CH=CH 
 
 
 
C.        D.     
 
 
 
 
E.        
Z = CH2,  R = CH3 
Z = CH2,  R = SCH3 
Z = CH2,  R = iBu 
Z = CH2,  R = CH2Ph 
     Z = O,    R = CH3 
     Z = O,     R = CH2CH3 
 
Figure 14: DDl inhibitors, analogues of the transition state. A) D-alanyl phosphate – 
the template, B) 3-amino-2-oxoalkylphosphonic acid, C) DDl transition state – 
the template, D) phosphorylated phosphinate/phosphonate inhibitor 
E) phosphinate/phosphonate inhibitor 
 
DDl is also inhibited by phosphinic and phosphonic acids. Series of phosphinic 
acid inhibitors, DDl transition state (see Figure 14/C) analogues have been synthetised 
more than 20 years ago. The best of these compounds showed to be potent and 
essentially irreversible inhibitors of D-Ala-D-Ala ligase. A mechanism for the inhibition 
of D-Ala-D-Ala ligase by these compounds is proposed to involve an ATP-dependent 
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formation of phosphorylated inhibitor (structures see Figure 14/D, inhibitor in binding 
site see Figure 15) within the enzyme's active site. The antibacterial activities of these 
compounds are modest probably due to poor transport inside the bacteria, although their 
spectra include both Gram-positive and Gram-negative susceptible organisms. The best 
antibacterial activity was shown by 1(S)-aminoethyl-(2-carboxy-2(R)-methylthio-
1-ethyl)phosphinic acid (Ki = 1.2 μM) closely followed by 1(S)-aminoethyl-(2(R)-
carboxy-1-n-propyl)phosphinic acid and other phosphinic acids with larger groups 
in R position (see Figure 14/E) (36). 
Other phosphinates and newly also phosphonates were synthesized in other 
study. The latter compounds are analogues in which the group in the amino position is 
changed from methylene to oxygen (see Figure 14/E). These compounds were 
evaluated as inhibitors of DDlA, DDlB and VanA enzymes. DDlA is strongly inhibited 
by phosphinates but not by phosphonates, while both phosphinates and phosphonates 
inhibit DDlB strongly and VanA weakly (19). 
 
 
 
 
 
 
 
 
 
Figure 15: 
DDlB of E. Coli with phosphorylated phosphinate inhibitor and ADP (37). 
 
Crystallographic structures of the DDlB and VanA complexed with phosphonate 
and phosphinate were also studied. In each complex the inhibitor has reacted with ATP 
to produce ADP and a tight-binding phosphorylated transition state intermediate. These 
two structures were compared with the known crystal structure of the phosphinate 
intermediate. DDlB complex shows no major conformational changes, but differences 
in mobility of loops covering the binding site. VanA complex lost one interloop 
hydrogen bond, which is supposed to cause previously observed weaker inhibition 
by both inhibitors (38). 
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Other inhibitors 
A.          B. 
 
 
 
 
C.      D. 
 
 
 
 
E.        F. 
 
 
R1,R2 = OH quercetin  
R1,R2 = H apigenin 
 
 
 
G.         H.     R1 = OCH3, R2 = H 
         R1 = F,         R2 = H 
 
 
 
 
I. 
 
 
 
Figure 16: Other inhibitors of DDl. A) Diazenedicarboxamide, B) DDl inhibitor 
selected from NCI database C) LFM-A13, D) Tyrphostine 47, E) Pfizer´s DDl inhibitor, 
F) Flavonoid inhibitors, G) De novo designed cyclopropyl-based inhibitor, H) De novo 
designed hydroxyethylamine inhibitors, I) Example of de novo designed 
2-phenylbenzoxazole inhibitors 
 
Over the last 3 years, several new inhibitor scaffolds have been published that 
show no structural similarity with the substrate, the product or an intermediate 
of the reaction, but proved to be potent inhibitors of D-ala-D-ala ligase activity. These 
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scaffolds were evidenced either by screening or by modeling, indicative of the currently 
more promising routes for drug discovery (6). 
Together on Pharmacy and Chemistry faculties of Ljubljana University and 
on University of Leeds, screening of various synthetized compounds was performed 
to find out new DDl inhibitors. Diazenedicarboxamides appeared to be the most 
promising. Consequently synthetised serie of different diazenedicarboxamides revealed 
good DDl inhibition ability, in some cases better than D-cycloserine. For example 
(E)-N-(3-chlorophenyl)-N'-(pyridin-3-ylmethyl)diazene-1,2-dicarboxamide (see Figure 
16/A) has IC50 = 50 μM. Also antibacterial activity of some of these compounds is 
signicifant (39). 
A virtual screening of the 1990 molecules of the NCI (National Cancer Institute) 
database was performed on the same workplaces using AutoDock 4.0 and the DDlB 
model, which allowed to select the 130 topranked compounds for in vitro assay. These 
compounds were tested in an in vitro assay for their inhibition of E. coli DDlB. Three 
compounds that inhibit the enzyme with Ki values in micromolar range were identified 
(see one of these three compounds on Figure 16/B, its Ki = 11 μM). Two of these 
derivatives have also promising antibacterial activities against Gram-positive and 
Gram-negative bacteria. These compounds, however, are likely to be toxic, as they were 
submitted to the NCI for potential activity as anticancer agents (40). 
Researchers from Max Planck Institute of Molecular Physiology in Dortmund 
also identified new inhibitor scaffolds for DDl. Their research was based on similarity 
in the ATP binding region of different kinases and DDl. In tests of different ATP 
competitive protein kinase inhibitors they have found that substance LFM-A13 (see 
Figure 16/C), analog of metabolite of antirheumatic drug Leflunomide (Arava®) 
inhibits DDl with Ki = 185 μM. Also Tyrphostine 47 (see Figure 16/D) (which is 
tyrosin kinase inhibitor) was found to inhibit DDl activity well with Ki = 290 μM (41). 
Another research in Pfizer company in Groton found out interesting DDl 
inhibitor 3-chloro-2,2-dimethyl-N-[4(trifluoromethyl)phenyl]propanamide (see Figure 
16/E), its Ki = 4 μM against DDl of Staphylococcus aureus. The research also revealed 
important fact that inhibitor-binding site in DDl does not overlap with any D-Ala 
binding sites (see Figure 17) and inhibitors with this binding mode potentially could 
overcome vancomycin resistance (27). 
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Figure 17. DDl ligand-binding sites (27). The protein surface shows ligands, 
particularly ADP, the phosphorylated phosphinate and Pfizer´s DDl inhibitor. The last 
mentioned compound has binding site in DDl which does not overlap with any D-Ala 
binding sites. 
 
Researchers from Chinese Academy of Sciences in Shanghai tested various 
natural compounds for potential DDl inhibition activity. Quercetin 
(3,3',4',5,7-pentahydroxyflavone) and apigenin (4',5,7-trihydroxyflavone) (see Figure 
16/F) are two representative flavonoids, both of which have been reported previously 
to possess antibacterial activity by acting on multiple targets (DNA gyrase, fatty acid 
biosynthesis, membrane). There was determined that DDl is also target for quercetin 
and apigenin. Kinetic analysis indicated that these two flavonoids function as reversible 
inhibitors that are competitive with the substrate ATP of DDl, whereas they are 
non-competitive with the other substrate D-Ala. Quercetin showed lower Ki values 
(10 μM) than apigenin (119 μM) against tested DDls (42). 
 
 
 
 
 
 
 
 
 
Figure 18. The bonding interactions of cyclopropyl inhibito within DDl active site 
(43). 
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New inhibitors were revealed also with help of de novo structure-based 
molecular design (program SPROUT). A cyclopropyl-based amino acid (for structure 
see Figure 16/G, for inhibitor in its binding site see Figure 18) was designed, 
synthetised and tested on University of Leeds. It had an apparent Ki = 12.5 μM 
for DDlB, but no activity against the VanA ligase (43). 
The group of Faculty of Pharmacy in Ljubljana used de novo molecular 
designing program SPROUT in conjunction with the X-ray crystal structure of VanA 
ligase to design new inhibitors based on a hydroxyethylamine template. The two best 
ranked structures were selected and synthetised (see Figure 16/H). The inhibitory 
activities of these molecules were determined on E. faecium VanA and on DDlB 
from E. coli. Hydroxyethylamines inhibit 75 to 83 % of the activity of both DDlB and 
VanA ligases at 500 μM (44). 
De novo design was used by Tytgat et al. to develop other group of DDl 
inhibitors. At the begining four softwares (LUDI, MCSS, Autodock and Glide) 
developed either for fragment or full-molecule docking were compared and scored. 
Then a short series of novel derivatives based on a 2-phenylbenzoxazole scaffold was 
rationally designed de novo on the basis of computational data and they were 
synthesized and tested. The best benzoxazole compound (structure see Figure 16/I, 
docked inhibitor see Figure 19) was found to fully inhibit the D-alanyl-D-alanine ligase 
of E. faecalis with an IC50 of 400 μM which is close to that of D-cycloserine. This best 
inhibitor also showed to be active on inhibition of bacterial growth of Gram-positive 
bacteria (45). 
 
 
 
 
 
 
 
 
 
 
Figure 19: Docked benzoxazole inhibitor in the E. coli D-Ala-D-Ala ligase 
enzymatic pocket. On figure can be seen also ATP and two magnesium ions (45). 
SUCHANOVÁ KLÁRA                                                                                     DIPLOMOVÁ PRÁCE    
32 
3. Experimental work preface 
 
Our practical research work was focused on D-ala-D-ala ligase (DDl). To design 
potential DDl inhibitors we used docking software (AutoDock 4.05, The Scripps 
Research Institute, La Jolla, USA) to dock potential DDl inhibitors into available X-ray 
structures of DDl (1IOW and 1IOV, PDB). According to the in silico design, we have 
choosen target molecules for the synthesis and tried to synthetize all designed 
molecules. 
 
3.1. In silico design 
In past years, several structures of DDl have been solved by X-ray 
crystallography, giving a detailed view of the general topology of the active site and 
of the residues in the catalytic pocket that play a central role in substrate recognition. 
This has paved the way to the rational design of inhibitors (38). 
When deciding which scaffold to use as a basis of our new potential inhibitor, 
we came out of the structures of D-Ala-D-Ala transition state, phosphorylated 
phosphinate inhibitor of Parsons et al. (36) and D-cycloserine structure (see Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Designing of our potential DDl inhibitors 
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Semi-flexible docking was carried out with the program Autodock 4.05. This 
software is quite fast, provides high quality predictions of ligand conformations and 
good correlations between predicted inhibition constants and experimental ones. 
In the docking, the macromolecular receptor was treated as a rigid body, but all 
the torsions in the ligand were allowed to freely rotate. The structure of our compounds 
was derived from the geometry obtained by a full optimization. The energy grid maps 
were calculated according to ligand atom types. The reasonable complex model was 
selected and the docking results were ranked according to the lowest docked energy, 
the highest populated cluster and the best geometric matching. Final predictions of Ki 
and free energies of binding are presented in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Predicted inhibition constants and estimated free energy of binding 
of designed DDl inhibitors. 
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Known DDl inhibitors (see chapter 2.6) have one thing in common, that is low 
Ki, which is in some cases in μM range (e.g. phosphinates), but on the other hand these 
enzyme inhibitors have poor antibacterial effect. This is because of poor ability to cross 
cytoplasmatic membrane, these molecules are large, polar or negatively charged (6).  
Our designed structures are more rigid, more lipofilic and smaller with 
isothiazolidinone core with residues of various aminoacids on it. Sulfonate group 
mimics phosphate group of phosphorylated carboxy group of alanine and lowers 
the polarity of the molecule. The rest of the molecule is almost identical to native 
dipeptide and phosphinate inhibitor so we can assume the enzyme will be able 
to produce the same interactions. Furthermore, in contrast to the phosphorylated 
phosphinate inhibitor our isothiazolidinone ring is unable of ionization, which would be 
expected to significantly reduce poor distribution properties of phosphinate inhibitors. 
 
 
a) Docking pose of compound ASK-6 
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b) Docking pose of compound ASK-15 
 
c) Docking pose of compound ASK-16 
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d) Docking pose of compound ASK-24 
 
e) Docking pose of compound ASK-25 
 
Figure 21 a) - e): Docking poses (AutoDock 4.05) of designed DDl inhibitors into 
DDl active site (PDB code: 1IOV, (38)). Ligands are presented as a stick model, ADP 
is coloured green, designed inhibitor and phosphinate inhibitor are coloured in atom 
colours, Mg
2+
 atoms coloured blue, protein surface with red and blue representing 
negative and positive charges, respectively, white is for neutral. On picture a) there are 
significant contacting residues labeled and hydrogen bonds in green and dashed.  
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The docking poses (see Figure 21 a)–e)) predict that isothiazolidinone core lies 
analogically to cocrystalized phosphinate inhibitor, amine group is turned towards near, 
negatively charged center of Glu15. One of the sulfonic oxygens appeared to be 
anchoring in the same position as one of the oxygens in acylphosphate group 
in the native crystal structure. It forms a hydrogen bond within the binding site (Lys215) 
and creates a komplex with Mg
2+
 330 from the active site. The aminoacid substituents 
lies as expected along the phosphinate inhibitor with carboxylic group turned towards 
magnesium ions. The designed inhibitors seems to be imitating well D-Ala-D-Ala 
intermediate state in the same way as phosphinate analogue of D-ala-D-Ala is doing. 
The only surprise is the docked molecule ASK-25, which is turned in the pocket 
in a different way. The sulfonic oxygens are turned away from magnesium ions. 
On the contrary, the carbonyl oxygen from isothiazolidinone core faces and interacts 
with the magnesiom ion. 
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3.2. Synthesis 
 
Our target was to prepare new type of DDl inhibitors which will mimic 
acylphosphate intermediate of DDl native substrate. As a core we took isothiazolidinone 
heterocycle. According to our knowledge of structure-activity relationship, we predicted 
better permeability for designed, isothiazolidinone core-based compounds. 
As a first step we performed synthesis of heterocyclic isothiazolidinone core 
to mimic phosphorylated carboxy group of alanine (target compounds ASK-4 and 
ASK-6, see Synthetic scheme 1). We did not perform ASK-4 docking because it is 
basically the thio-analogue of D-cycloserine. ASK-4 was therefore just a reference 
molecule with which we wanted to verify whether 2 oxygens on sulfoxide add to 
the binding affinity. Furthermore we introduced D-alanine, D-aspartic acid, 
D-phenylalanine and β-alanine residues to complement our potential transition state 
dipeptide mimics of DDl (target compounds ASK-15, ASK-16, ASK-24, ASK-25, see 
Synthetic scheme 3). 
Reactions used during synthesis of designed inhibitors were usually based 
on known principles of peptide synthesis. We used tert-butyloxycarbonyl (Boc) and 
a benzyloxycarbonyl (Cbz) protection (see Figure 22) of amine groups of D-cystine 
(starting compound). These protective groups were chosen for their easy introduction, 
stability in the selected reaction conditions and the possibility of easy removal. 
The formation of protected amino acids was conducted under basic aqueous conditions 
(dioxane/water, NaOH), by reaction with electrophilic reagents Boc2O anhydride 
or benzyl chloroformate (46, 47). 
 
Figure 22: Cbz protection mechanism (47). 
 
The amide bond formation was performed on N-protected D-cystine derivatives 
with various carboxy-protected aminoacids (Ala, Asp, Phe, β-Ala). We used 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC) or N,N'-dicyclohexylcarbodiimide 
(DCC) as activating agent and N-hydroxybenzotriazole (HOBt) as auxiliary nucleophile 
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(see Figure 23). The EDC (or DCC) containing carbodiimide group was used 
to increase electrophilicity of carboxylic group of D-cystine through creation of O-acyl 
urea. As in the reaction by-products can be created (N-acyl urea and 5(4H)-oxazolones) 
we added an auxiliary nucleophile - HOBt. The latter reacts with O-acyl urea to form 
an activated ester, which is sufficiently reactive to be attacked by appropriate 
nucleophiles (in our case tert-butylamine or various aminoacids). Urea derivatives 
created by this procedure were removed wih subsequent washing with basic water 
solutions in case of EDC or were filtered off in case of DCC. All reactions were 
conducted in N,N-dimethylformamide (DMF) as a solvent and gave good yields (46, 
47). 
Above mentioned aminoacids (Ala, Asp, Phe, β-Ala) were protected in form 
of benzyl esters prepared in the acid-catalyzed esterification. p-Toluenesulfonic acid 
was used as an acid catalyst to perform esterification. Water formed during reaction was 
caught in a Dean-Stark trap, and so separated from the reaction mixture. Reaction was 
performed in toluene and benzylalcohol. We did not succeed to protect aminoacid 
4-fluoro-D-α-phenylglycine only (46). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Formation of amides with EDC and HOBt reagents (47). 
 
SUCHANOVÁ KLÁRA                                                                                     DIPLOMOVÁ PRÁCE    
40 
The most important step of synthesis was cyclization reaction using bromine 
at low temperature to create isothiazolidinone core. This reaction consists of formation 
of sulfenyl bromides (see Figure 24) and following intramolecular attack of amide 
nitrogen. Cyclization was performed in an argon atmosphere with dry dichloromethane 
as a solvent at -80 °C. Bromine was used for preparation of sulfenyl halides. It attacks 
disulfidic bond of the starting molecule, trigonal transition state is formed, which is 
followed by sulfenyl bromide creation (47, 48, 49). 
 
Figure 24: Formation of sulfenyl bromides (47). 
 
This reaction was usually followed by oxidation with m-chloroperoxybenzoic 
acid (mCPBA) (see Figure 25). After cyclization we had a mixture of non- and 
mono-oxidized products and we continued with oxidation in next step to obtain more 
stable dioxide form usually without product separation. We can regard a non-oxidized 
product as a masked sulfenic acid so the reaction consists of nucleophilic attack 
on the peroxide oxygen of electrophilic mCPBA with the formation of carboxylic acid 
and an oxygenated product (47, 48, 49). 
 
Figure 25: Sulfene oxidation with mCPBA (47). 
 
At last we had to deprotect protecting groups. We used either microwave-assisted 
deprotection with trifluoroacetic acid (TFA) or deprotection via catalytic hydrogenation 
using palladium on activated charcoal as a catalyst in absolute ethanol or glacial acetic 
acid as a solvent. Microwave (MW) chemistry is based on fact, that molecules 
with a dipole absorb microwave radiation, which is converted into heat with high 
efficiency. If superheating is performed in closed vessels under high pressure, a reaction 
that takes several hours under conventional conditions can be completed over the course 
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of minutes. We used MW for deprotection of tert-butyl and Boc protected compound. 
Cleavage of this groups was made under anhydrous acidic (TFA) conditions, heated 
usually with power 30 W on temperature 120 °C for 5 minutes, and this temperature 
was held for 25 minutes. The other Cbz-protected compounds were deprotected by 
catalytic hydrogenation of carbon-palladium in anhydrous ethanol (see Figure 26). We 
had to handle with the catalyst very carefully as it can reacts with oxygen promptly and 
ignites (46, 47, 50, 51). 
Figure 26: Mechanism of catalytic hydrogenation, Cbz deprotection (47). 
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4. Materials and methods 
 
Reagents and solvents: 
Chemicals and solvents were obtained from Sigma-Aldrich, Acros Organics, Carlo Erba 
Reagents, Fluca and Merck companies and used without further purification. 
 
Software: 
 CambridgeSoft - ChemOffice2008 (especially ChemDraw) and ACD/Labs – 
ACD/ChemSketch 12.0 for writing structures and computing of stechiometric and other 
data. 
 MestReC and Mnova Suite (6.0.4) programme distributed by Mestrelab 
Research company – for processing pictures of FID signals, COSY spectra and other 
NMR data. 
 
Chromatographic methods: 
 TLC analytical chromatography was performed by using Merck Kieselgel 60 
F254 aluminium plates with 0.2 mm thin layer of silica gel and addition of fluorescent 
indicator. For detection of spots we used darkroom cabinet with UV lamp ( λ = 254 nm) 
and sprayer with ninhydrin. 
 For purification of our products we used column chromatography with Merck 
silica gel, size 0.063-0.200 mm for standard and 0.040-0.063 mm for "flash" column 
chromatography. 
 We used also automatic chromatographic 
purification system Isolera™ (Figure 27), 
a device developped by Biotage company, we 
worked with pre-filled SNAP cartridges filled 
with normal "flash" 32-63 µm silica gel 
for normal-phase chromatography and C18 
32-63 µm silica gel for reversed-phase 
chromatography. We also used cartridges 
re-filled manually with 0,040-0,063 mm silica 
gel. 
    Figure 27: Isolera™ machine 
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Melting point determination: 
We determined the melting point of our substances on PolythermA Heiztischmikroskop 
(Wagner & Munz) with melting bench. 
 
Nuclear magnetic resonance: 
1
H NMR spektroscopic data were recorded on Brucker Avance DPX 300 spectrometer 
at r.t. with inner standard tetramethylsilane in National High Resolution NMR 
Spectroscopy Centre in Ljubljana. Samples were dissolved in solvents: DMSO-d6, 
CDCl3 or D2O with addition of NaOD. 
Rarely we asked for two dimensional NMR spectroscopy analysis to receive COSY 
spectrum for better uderstanding of composition of our samples. 
 
Mass spectrometry: 
MS spectra were recorded on spectrometer Varian-MAT 311 A with FAB and ES 
ionisation method on Jožef Stefan Institute in Ljubljana. 
 
Infrared spectroscopy: 
IR spectra were recorded on spectrophotometers Perkin Elmer 1600 FT-IR and Nicolet 
Nexus FT-IR on Faculty of Pharmacy in Ljubljana. 
 
Microwave reactor: 
We used microwave reactor CEM 
Discover (Figure 28) with single-mode 
irradiation, infrared or fiber-optic 
temperature monitoring 
in the microwave-assisted synthesis and 
pressure-control system that ensures 
operator safety by offering an automated 
overpressure venting capability. We 
used also CEM’s Synergy™ software 
for commanding, controling and 
recording of processes.         Figure 28: CEM Discover reactor 
 
SUCHANOVÁ KLÁRA                                                                                     DIPLOMOVÁ PRÁCE    
44 
Immerse cooler: 
For advanced cooling we used immerse cooler Julabo 
FT 901 (Figure 29) which have flexible immersion 
probe and external Pt100 temperature sensor, range 
of temperatures is -90 to +30 °C. 
 
 
 
 
 
 
Figure 29: Immerse cooler Julabo FT 901 
 
Filtration: 
Besides classical filtration methodes like glass funnel + 
cotton and Büchner funnel + filter paper we did also 
high-quality filtration using Sigma-Aldrich´s vacuum 
filtration assembly (Figure 30) with Fluoropore™ PTFE 
filter membranes with pores of diameter 0,2 μm. 
 
 
 
 
 
 
         Figure 30: Vacuum Filtration assembly with PTFE filter 
 
Drying and evaporation: 
For drying of our products we were using drying oven, for thermolabile substances we 
used freeze-dryer. For evaporating of solvents and for drying of some products we used 
BÜCHI Rotavapor R-114 with Waterbath B-480. 
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5. Experimental work 
 
5.1. Synthetic schemes 
5.1.1. Scheme 1: Synthesis of Boc-protected isothiazolidin-3-on-4-amines 
 
 
                                  Target molecule 1           Target molecule 2 
 
5.1.2. Scheme 2: Attempted synthesis of p-toluenesulfonate of 4-fluoro-D-α-
phenylglycine-benzyl ester 
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5.1.3. Scheme 3: Synthesis of Cbz-protected isothiazolidin-3-on-4-amines 
 
 
 
 
 
 
 
  Target molecules 3 and 4 
 
 
 
 
       Target molecules 5 and 6 
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5.2. Synthetic procedures and results of analysis 
 
5.2.1. Synthesis of N,N´-diBoc-protected D-cystine (ASK-1)  
 
Reaction scheme: 
 
D-cystine (1 g, 4.17 mmol) was weighted into 50 ml round-bottom flask, dispersed 
in 10 ml of 1,4-dioxane, 10 ml of water and a magnet was added. While it was mixed 
on an.ice bath, 2.05 ekv. of NaOH (8.54 ml of 1M solution, 8.54 mmol) was added 
carefully (by drops) untill the whole amount of D-cystine was dissolved (if necessary, 
ultrasound was used for better dissolving). Into cooled solution of D-cystine sodium salt 
2.1 ekv. of Boc anhydride (1.9 g, 8.75 mmol) dissolved in 10 ml of 1,4-dioxane was 
added by dropping funnel during 30 minutes. The ice bath was removed and 
the reaction mixture was allowed to warm to room temperature. The reaction was left 
to run for 2 hours at r.t. and constant pH = 8-9 (adjusted by adding drops of 1M solution 
of NaOH). After the reaction was finished, 10 ml of water was added and 1,4-dioxane 
was evaporated on rotary evaporator. 40 ml of water was added to the residue, which 
was acidified on an ice bath by adding drops of 1M solution of HCl untill pH = 2. Thick 
white precipitate appeared, which was filtrated on Büchner funnel and washed several 
times with water. Product was dried in drying machine at temperature 60-70 °C for two 
hours (46, 47). 
 
Description: white amorphous substance 
Yield: 1.57g, 85.7 %  
Rf (CH3CN/MeOH/H2O = 3/1/1): 0.83 
Tm: 109.1 °C 
1
H NMR (300MHz, D2O + NaOD): δ = 1.39 (9H, s, 3× -CH3), 2.88 (1H, dd, J = 
10.5 Hz, 2.7 Hz, -S-CH2-R), 3.18 (1H, d, J = 10.5 Hz, -S-CH2-R), 4.15-4.19 (1H, m, 
-CH-) ppm. 
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IR νmax: 3391, 2984, 1685, 1586, 1518, 1408, 1297, 1166, 1056 cm
-1
 
MS m/z: 439 [M-H]ˉ 
HRMS (TOF ESI+): calculated for C16H27N2O8S2 439.1209, found 439.1210 
 
5.2.2. Synthesis of di-tert-butyl(N,N'-diBoc-D-cystin)-di-amide (ASK-2) 
 
Reaction scheme 1: with HOBt and EDC 
 
Reaction scheme 2: with DCC 
  
Substance ASK-1 (1.5 g, 3.5 mmol) was weighted into 50 ml round-bottom flask, 
dissolved in 10 ml of DMF, a magnet was added and the mixture was placed on an ice 
bath. Into cooled reaction mixture were carefully pipetted 4 ekv. of tert-butylamine 
(1.47 ml, 13.88 mmol) and added 2.4 ekv. of HOBt (1.125 g, 8.33 mmol) and 2.6 ekv. 
of EDC (1.73 g, 9.02 mmol). The reaction was left to run for 24 hours at room 
temperature. Then the solvent was evaporated on rotary evaporator, the rest was 
dissolved in 40 ml of DCM and transferred into separating funnel. The organic phase 
was washed 3× with 20 ml of 10% m/m solution of citric acid, 3× with 20 ml 
of saturated solution (s.s.) of NaHCO3 and 1× with 50 ml of s.s. of NaCl. It was dried 
with Na2SO4 and the solvent was evaporated (46, 47). 
The product was purified using Isolera medium pressure liquid chromatography system 
with mobile phase EtOAc/Hexane (gradient separation). 
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There is also possibility to use more toxic DCC instead of EDC. Only change 
in procedure is filtration of reaction mixture before evaporating and extraction (to get 
rid of created solid urea derivative). 
 
Description: white amorphous substance 
Yield: 0.91g, 47.4 % (when EDC used), 1.86 g, 97.6 % (when DCC used) 
Rf (EtOAc/Hexane = 1/1): 0.81 
Tm: 124.1 °C 
1
H NMR (300MHz, CDCl3): δ = 1.41 (9H, s, -tBu), 1.48 (9H, s, -tBu), 2.96 (2H, d, 
J = 7.2 Hz, -CH2-S-), 4.55-4.62 (1H, m, -CH-), 5.52 (1H, d, J = 9.3 Hz, -NH-COO-), 
6.91 (1H, s, -NH-CO-) ppm. 
IR νmax: 3351, 2978, 1664, 1542, 1458, 1393, 1366, 1251, 1169, 1049, 1024 cm
-1
 
MS m/z: 551 [M+H]
+
, 573 [M+Na]
+ 
HRMS (TOF ESI+): calculated for  C24H47N4O6S2 551.2937, found 551.2939 
 
5.2.3. Synthesis of 2-(tert-butyl)-4-(tert-butoxycarbonylamino) 
isothiazolidin-3-one (ASK-3) 
 
Reaction scheme: 
 
Substance ASK-2 (0.86 g, 1.6 mmol) was weighted into dried 50 ml two-neck 
round-bottom flask. A was added magnet, both necks were closed with rubber septa and 
argon was let to flow through the system for a while. 20 ml of distilled DCM and 
0.75 ml of pyridine was added with syringe and started to mix. The reaction mixture 
was subsequently cooled down on -80 °C in an acetone bath cooled with immersion 
cooler (Apparatus on Figure 31). Then 2.5 ekv. of bromine (3.92 ml of 1M solution 
in DCM, 3.92 mmol) was added with syringe slowly for 30 minutes. After bromine was 
added, the reaction mixture was lifted from an acetone bath to slowly heat back on room 
temperature. After 2 hours 5 ml of 10mM solution of Na2S2O3 was added with syringe, 
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organic phase was separated in separating funnel and the organic phase was washed 3× 
with 15 ml of 15% m/m solution of NaHSO4 and 1× with 20 ml of s.s. of NaCl. 
The organic phase was dried using Na2SO4 and the solvent was evaporated (47, 48, 49). 
Isolera medium pressure liquid chromatography was performed with mobile phase 
EtOAc/Hexane (gradient) to separate reduced form (ASK-3a) from S-monoxide form 
(ASK-3b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Cyclisation reaction apparatus with immerse cooler. It consists 
of magnetic stirrer (1), crystallizing dish (2) which is laid on and wrapped in isolation 
(3). Inside of the dish there is a magnet, contact thermometer (4), immersion cooler (5) 
and acetone cooling bath (6). In acetone two-neck round-botoom flask is placed (7) 
with necks closed with rubber septa (8). Inside of the flask, there is our reaction mixture 
(9) and a magnet. One rubber septum is constantly perforated with needle of argon filled 
baloon (10), the second septum is perforated by syringe (11) when bromine is being 
added into reaction mixture. 
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Description: yellowish oily substance 
Yield (ASK-3): 0.46 g, 54.6 % 
Rf (EtOAc/Hexane = 1/2): 0.70 
1
H NMR (300MHz, CDCl3): δ = 1.47 (9H, s, -tBu), 1.52 (9H, s, -tBu), 3.24 (1H, t, J = 
10.8 Hz, -CH2-S-), 3.77-3.82 (1H, m, -CH2-S-), 4.39-4.44 (1H, m, -CH-), 5.33 (1H, s, 
-NH-COO-) ppm. 
IR νmax: 3280, 2969, 1708, 1625, 1525, 1327, 1157, 1048 cm
-1
 
MS m/z: 275 [M+H]
+
, 297 [M+Na]
+ 
HRMS (TOF ESI+): calculated for  C12H23N2O3S 275.1429, found 275.1426 
 
5.2.4. Synthesis of 4-amino-isothiazolidin-3-one hydrochloride (ASK-4) 
 
Reaction scheme: 
 
Substance ASK-3a (0.201 g, 0.7 mmol) was dissolved in 2 ml of distilled DCM and 
transferred into MW reaction tube. Then 5 ml of TFA was added and the reaction 
mixture was mixed and bubbled with argone. The MW tube was closed with teflon cap. 
For next step microwave reactor was used to perform the reaction. The reaction tube 
was heated with power 30 W on temperature 120 °C for 5 minutes, and while mixing 
this temperature was hold for 25 minutes. Attention was paid not to increase pressure 
over 20 bars. When the reaction was finished, DCM and TFA were evaporated and 
2 ekv. of concentrated solution of HCl (37%) were added. It was mixed and then 
evaporated again. It was triturated with 10 ml of EtOEt and the white precipitate was 
filtrated with teflon filter (46, 50, 51). 
The product was purified using Isolera medium pressure liquid reversed-phase 
chromatography with mobile phase 0.1% TFA/H2O 95 % → 25 %, AcCN 5 % → 75 %. 
The solvent was evaporated almost till the end and the rest was dried on freeze drier. 
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Description: creamy-white coloured powder 
Yield: 0.089g, 46.3 % 
Rf free base (DCM/MeOH = 4/1): 0.53 
Tm: 85.8 – 142.1 °C 
1
H NMR (300MHz, CDCl3): could not be solved, unseparable mixture of compounds 
IR νmax: 3420, 1724, 1639, 1566, 1506, 1368, 1301, 1177 cm
-1
 
MS m/z: 141 [M+Na]
+
 
 
We failed to prepare compound ASK-4 in sufficient quantity and purity, but MS 
showed that we have obtained at least a small amount of our compound. 
 
5.2.5.  Synthesis of 2-(tert-butyl)-4-(tert-butoxycarbonylamino)- 
isothiazolidin-3-on-S,S-dioxide (ASK-5) 
 
Reaction scheme: 
 
Substance ASK-3b (0.26 g, 0.96 mmol) was weighted in 50 ml round-bottom flask and 
dissolved in 5 ml of distilled DCM. While it was mixing, 2.2 ekv. of mCPBA 
(2.11 mmol, 0.473 g (77%)) was added. The flask was closed and the reaction was left 
to run for 24 hours at r.t. After this period the solvent was evaporated at temperature not 
exceeding 40 °C. The residue was dissolved in 15 ml of EtOAc and transferred 
into separating funnel. Organic phase was washed 1× with 15 ml of s.s of NaHCO3, 3× 
with 20 ml of 10% m/V solution of citric acid and 1× with 30 ml of s.s. of NaCl. 
Organic phase was dried with Na2SO4 and then the solvent was evaporated (47, 48, 49). 
The product was purified using column „flash“ chromatography with mobile phase 
EtOAc/Hexane = 1/4. 
 
Description: yellowish oily substance 
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Yield: 0.16 g, 54 % 
Rf (EtOAc/Hexane =1/2): 0.50 
1
H NMR (300MHz, CDCl3): δ = 1.48 (9H, s, -tBu), 1.67 (9H, s, -tBu), 3.50 (1H, t, J = 
9.9 Hz, -CH2-S-), 4.09-4.18 (1H, m, -CH2-S-), 4.66-4.70 (1H, m, -CH-), 5.32 (1H, s, 
-NH-COO-) ppm. 
IR νmax: 3384, 2979, 2362, 1715, 1516, 1458, 1395, 1369, 1337, 1259, 1230, 1148, 
1049 cm
-1
 
MS m/z: 307 [M+H]
+
, 329 [M+Na]
+
, 345 [M+K]
+ 
HRMS (TOF ESI+): calculated for C12H23N2O5S 307.1328, found 307.1338 
 
5.2.6. Synthesis of 4-amino-isothiazolidin-3-on-S,S-dioxide  
trifluoroacetate (ASK-6) 
 
Reaction scheme: 
 
Substance ASK-5 (0.12 g, 0.4 mmol) was dissolved in 3 ml of destilled DCM and 
transferred into MW reaction tube. Afterwards, 2.5 ml of TFA was added and argon was 
bubbled in while stirring the reaction mixture. The MW tube was closed with teflon cap. 
The reaction tube was irradiated with MW, power 30 W to reach the goal temperature 
of 120 °C for 5 minutes, and then for 25 minutes maintaining this temperature. 
The pressure did not exceed the safety limit of 20 bars. When the reaction was finished, 
the solvent was evaporated and the product triturated with 10 ml of EtOEt (46, 50, 51). 
 
Description: white amorphous substance 
Yield: 0.055 g, 99 % 
Rf free base (CH3CN/MeOH/H2O = 3/1/1): 0.52 
Tm: 232.5 °C 
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1
H NMR free base (300MHz, CDCl3): δ = 3.74 (1H, dd, J = 9.2 Hz, 4.1 Hz, -CH2-S-), 
4.10 (1H, dd, J = 9.2 Hz, 4.1 Hz, -CH2-S-), 5.17 (1H, t, J = 9.2, -CH-) ppm. We did not 
observe the peak for -NH- protone. 
IR νmax: 3360, 1748, 1716, 1558, 1349, 1156 cm
-1
 
MS m/z : 149 [M-H]ˉ 
 
5.2.7.  Synthesis of p-toluenesulfonate of 4-fluoro-D-α-phenylglycine- 
benzyl ester (ASK-7) 
 
Reaction scheme: 
4-fluoro-D-α-phenylglycine (1.46 g, 8.6 mmol) was added with 1.02 ekv. 
of p-toluenesulfonic acid monohydrate (1.67 g, 8.8 mmol) to the mixture of 10 ml 
of benzylalcohol and 10 ml of toluene in 100 ml round-bottom flask. The apparatus 
for azeotropic distillation was prepared (Figure 32). The mixture was heated to reflux 
(temperature approximately 140 °C) and the water formed in the reaction was trapped 
in a Dean-Stark receiver (trap). The azeotropic distillation proceeded overnight. 
The distillation was stopped and the reaction mixture was cooled on r.t. After diluting it 
with 50 ml of EtOEt, the reaction mixture was cooled on an ice bath for one hour while 
mixing. White product crystallised. It was filtrated on Büchner funnel, washed several 
times with more EtOEt and dried in drying oven for 1 hour on 50 °C temperature. 
The crude residue was dissolved in EtOAc and extracted with NaHCO3, filtrated and 
dried (46).  
 
Description: shiny soft white crystalic substance 
Rf (DCM/MeOH = 4/1): 0.78 
Tm: 231.6 °C 
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1
H NMR (300MHz, DMSO-d6): δ = 2.29 (3H, s, -CH3), 4.02 (2H, s, -CH2-), 7.10-7.30 
(4H, m, 4× -CH- from fluorophenyl group), 7.47-7.53 (4H, m, 4× aromatic -CH- 
from p-toluene group) ppm. It didn´t confirmed that our substance we received is 
p-toluenesulfonate of 4-fluoro-D-α-phenylglycinebenzylester. 
IR νmax: was not measured due to bad result from other analysis 
MS m/z: did not confirm that our substance we received is p-toluenesulfonate 
of 4-fluoro-D-α-phenylglycinebenzylester 
 
We failed to prepare compound ASK-7 in sufficient quantity and purity. 
 
Figure 32: Azeotropic distillation 
apparatus. It consists of hotplate 
magnetic stirrer (1) on which a vessel 
with oil bath is placed (2) in which 
a thermometer (3) and a round-bottom 
flask with reaction mixture (4, 
equipped with a magnet stirrer) are 
immersed. The neck of the flask is 
connected with Dean-Stark receiver 
(5). While the reaction proceeds, 
the reaction mixture reflux and 
an azeotrope which condenses 
in a condenser (8) attached to 
the upper part of the receiver flows 
down and separates in lower part 
of the receiver (trap). In our case 
denser constituent - water (6) remains 
in the trap and less dense constituent - 
toluene (7) flows back when the trap 
is filled. 
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5.2.8. Synthesis of N,N´-diCbz-protected D-cystine (ASK-8) 
 
Reaction scheme: 
 
D-cystine (0.8 g, 3.3 mmol) was weighted into 50 ml round-bottom flask, disperged 
in 10 ml of H2O and 10 ml of 1,4-dioxane, a magnet was added and the mixture was 
placed on an ice bath. When it was cooled to desired temperature, 2 ekv. of NaOH 
(6.54 ml of 1M solution, 6.54 mmol) were added dropwise and D-cystine dissolved. 
Into cooled solution of D-cystine sodium salt were added 2.3 ekv. of benzyl 
chloroformate (2.87 ml of 45% solution with toluene, 7.5 mmol) by drops 
for 30 minutes. Then the ice bath was removed allowing the reaction micture to warm 
to room temperature. The pH of the reaction mixture was constantly monitored during 
the  run of the reaction and adjusted to the value 8-9 by adding 1M solution of NaOH. 
After 20 hours 1,4-dioxane and toluene were evaporated on rotary evaporator. 
The residue was diluted with 30 ml of water and transferred into separating funnel. 
The alkaline water phase was extracted 3× with 20 ml of diethylether. The water phase 
was returned into flask and placed into ice bath. It was acidified by adding drops of 1M 
solution of HCl untill pH = 3. Thick white amorphous precipitate appeared, that was 
filtered on Büchner funnel and washed several times with water. The solid product was 
dryed for 2 days at room temperature (47, 51). 
 
Description: white amorphous substance 
Yield: 1.28 g, 77 % 
Rf (CH3CN/MeOH/H2O = 3/1/1): 0.79 
Tm: 70.9 °C 
1
H NMR (300MHz, DMSO-d6): δ = 2.92 (1H, dd, J = 9.8 Hz, 3.9 Hz, -CH2-S-), 3.19 
(1H, dd, J = 9.8 Hz, 3.9 Hz, -CH2-S-), 4.25-4.32 (1H, m, -CH-), 5.04 (2H, s, -CH2-), 
7.35 (5H, s, -CHAr-), 7.65 (1H, d, J = 8.1, -NH-) ppm. 
IR νmax: 3336, 3034, 1694, 1532, 1455, 1411, 1268, 1054 cm
-1
 
MS m/z: 509 [M+H]
+
, 531 [M+Na]
+
, 547 [M+K]
+ 
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HRMS (TOF ESI+): calculated for C22H25N2O8S 509.1052, found 509.1054 
 
5.2.9. Synthesis of N,N´-diCbz-D-cystinyl-di-D-phenylalanyl-benzyl 
ester (ASK-9) 
 
Reaction scheme: 
 
Substance ASK-8 (0.6 g, 1.2 mmol) was weighted into 50 ml round-bottom flask and it 
was dissolved in 10 ml of DMF and placed on an ice bath. Then 2 ekv. 
of p-toluenesulfonate salt of D-PheOBn (0.98 g, 2.36 mmol), 6 ekv. 
of N-methylmorpholine (NMM) (0.78 ml, 7.1 mmol), 2.4 ekv. of HOBt monohydrate 
(0.43 g, 2.83 mmol) and 2.6 ekv. of EDC (0.59 g, 3.1 mmol) were carefully added into 
cooled reaction mixture. The argon was bubbled in and reaction mixture stirred 
for 24 hours at room temperature. The solvent was evaporated on rotary evaporator and 
yellowish oil was dissolved in 20 ml of EtOAc (white precipitate appears) and 
transferred into separating funnel. The organic phase was washed 3× with 20 ml 
of 0.1M solution of HCl (precipitate dissolved after first addition of acid), acid water 
phases were re-extracted 2× with 10 ml of EtOAc. Combined organic fractions were 
washed 3× with 20 ml of s.s. of NaHCO3 and 1× with 40 ml of s.s. of NaCl. Organic 
phase was dried with Na2SO4, the drying agent filtered and the solvent evaporated to 
yield crude product (46, 47). 
The product was purified using column „flash“ chromatography with mobile phase 
EtOAc/Hexane = 1/1. 
 
Description: light brown crystals 
Yield: 0.756 g, 65.2 % 
Rf (EtOAc/Hexane = 1/1): 0.62 
Tm: 143.5 °C 
1
H NMR (300MHz, DMSO-d6): δ = 2.77 (1H, dd, J = 8.1 Hz, 3.6 Hz, -CH2-S-), 2.95-
3.05 (3H, m, -CH2-, -CH2-S-), 4.29-4.39 (1H, m, -CH-COO-), 4.51-4.58 (1H, m, 
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-CH-CO-), 5.03 (2H, s, -CH2-O-), 5.06 (2H, s, -CH2-O-), 7.20-7.34 (15H, m, -CHAr-), 
7.54 (1H, d, J = 8.7 Hz, -NH-COO-), 8.45 (1H, d, J = 7.8 Hz, -NH-CO-) ppm. 
IR νmax: 3310, 3032, 2364, 1719, 1690, 1654, 1534, 1454, 1313, 1269, 1183, 1041, 
1004 cm
-1
 
MS m/z: 983 [M+H]
+ 
HRMS (TOF ESI+): calculated for C54H55N4O10S2 983.3360, found 983.3333 
 
5.2.10. Synthesis of N,N´-diCbz-D-cystinyl-di-D-alanyl-benzyl ester  
(ASK-10) 
 
Reaction scheme: 
 
Substance ASK-8 (0.6 g, 1.2 mmol) was weighted into 50 ml round-bottom flask, 
dissolved in 10 ml of DMF and placed on ice water bath. Then 2 ekv. 
of p-toluenesulfonate salt of D-AlaOBn (0.83 g, 2.36 mmol), 6 ekv. of NMM (0.78 ml, 
7.1 mmol), 2.4 ekv. of HOBt monohydrate (0.43 g, 2.83 mmol) and 2.6 ekv. of EDC 
(0.59 g, 3.1 mmol) were carefully added into cooled reaction mixture. The ice bath was 
removed and the reaction mixture was left to warm slowly on room temperature. After 
stirring the reaction mixture for 24 hours at room temperature, the solvent was 
evaporated on rotary evaporator. The residue was dissolved in 20 ml of EtOAc (white 
precipitate appeared) and transferred into separating funnel. The organic phase was 
washed 3× with 20 ml of 0.1M solution of HCl (precipitate dissolved after first addition 
of acid), acid water phases were re-extracted 2× with 10 ml of EtOAc. Combined 
organic fractions were washed then 3× with 20 ml of s.s. of NaHCO3 and 1x with 40 ml 
of s.s. of NaCl. Organic phase was dried with Na2SO4, the drying agent filtered and the 
solvent evaporated to yield crude product (46, 47). 
The product was purified using column „flash“ chromatography with mobile phase 
EtOAc/Hexane = 1/1. 
 
Description: white crystallic substance 
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Yield: 0.78 g, 80 % 
Rf (EtOAc/Hexane = 1/1): 0.6 
Tm: 163.0 °C 
1
H NMR (300MHz, DMSO-d6): δ = 1.30 (3H, d, J = 7.2 Hz, -CH3), 2.82 (1H, dd, J = 
9.6 Hz, 2.4 Hz, -CH2-S-), 3.07 (1H, dd, J = 9.6 Hz, 2.4 Hz, -CH2-S-), 4.29-4.39 (2H, m, 
2x -CH-), 5.04 (2H, s, -CH2-O-), 5.1 (2H, s, -CH2-O-), 7.30-7.36 (10H, m, -CHAr-), 7.57 
(1H, d, J = 8.7 Hz, -NH-COO-), 8.47 (1H, d, J = 6.9 Hz, -NH-CO-) ppm. 
IR νmax: 3314, 3035, 1742, 1691, 1655, 1534, 1456, 1375, 1322, 1268, 1177, 1152, 
1046 cm
-1
 
MS m/z: 831 [M+H]
+
, 853 [M+Na]
+
, 869 [M+K]
+
 
HRMS (TOF ESI+): calculated for C42H47N4O10S2 831.2734, found 831.2770 
 
5.2.11. Synthesis of benzyl ester of 2-(4-(benzyloxycarbonylamino)- 
isothiazolidin-3-on-S,S-dioxid-2-yl)-3-fenyl propionic acid  
(ASK-13) 
 
Reaction scheme 1: 
 
Substance ASK-9 (0.485 g, 0.5 mmol) was weighted into dried 50 ml two-neck 
round-bottom flask. A magnet was added, both necks were closed with rubber septa and 
argon was let to flow through the system. 10 ml of distilled DCM and 0.5 ml of pyridine 
was added with syringe and started to mix. The reaction mixture was subsequently 
cooled down on -80 °C in an acetone bath cooled with immersion cooler. Then 2.5 ekv. 
of bromine (1.23 ml of 1M solution in DCM, 1.23 mmol) was added with syringe 
slowly for 60 minutes. After bromine was added, the reaction mixture was lifted from 
an acetone bath to slowly heat back on room temperature. After 2 hours 10 ml of 10mM 
solution of Na2S2O3 was added, organic phase was separated in separating funnel and 
washed 3× with 20 ml of 15% m/m solution of NaHSO4 and 1× with 40 ml of s.s. 
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of NaCl. The organic phase was dried using Na2SO4 and the solvent was evaporated 
(47, 48, 49). 
We obtained ASK-11 as a mixture of non- and mono-oxidized form and we continued 
with oxidation in next step to obtain dioxide form without product separation. 
 
Description: orange-brown oily substance 
Yield: 0.475 g, 98.1 % 
Rf: (EtOAc/Hexane =1/2): 0.42 
 
Reaction scheme 2: 
 
Substance ASK-11 (0.47 g, 0.95 mmol) was weighted in 50 ml round-bottom flask and 
dissolved in 10 ml of distilled DCM. While it was mixing, 2.2 ekv. of mCPBA 
(2.1 mmol, 0.47 g (77%)) was added. It dissolved. The flask was closed and the reaction 
was left to run for 24 hours at r.t. There appeared white precipitate at the end of this 
period. The solvent was evaporated at temperature not exceeding 40 °C. The white solid 
residue was dissolved in 20 ml of EtOAc and transferred into separating funnel. Organic 
phase was washed 2× with 20 ml of s.s of NaHCO3, 3× with 15 ml of 10% m/V solution 
of citric acid and 1× with 20 ml of s.s. of NaCl. Organic phase was dried with Na2SO4 
and then the solvent was evaporated (47, 48, 49). 
The product was purified using column „flash“ chromatography with mobile phase 
EtOAc/Hexane = 1/2. 
 
Description: light yellow oily substance 
Yield: 0.306 g, 61.32 % 
Rf (EtOAc/Hexane = 1/1): 0.57 
1
H NMR (300MHz, CDCl3): δ = 3.24 (1H, t , should be dd, J = 10.7 Hz, -CH2-), 3.43 
(1H, dd, J = 10.7 Hz, 3.9 Hz, -CH2-), 3.63 (1H, dd, J = 5.4 Hz, 9.2 Hz, -CH2-S-), 4.03 
(1H, dd, J = 5.4 Hz, 9.2 Hz, -CH2-S-), 4.78-4.86 (1H, m, -CH-), 4.89-4.94 (1H, m, 
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-CH-), 5.14 (2H, s, -CH2-O-), 5.22 (2H, s, -CH2-O-), 5.40 (1H, d, J = 4.5 Hz, -NH-), 
7.25-7.40 (15H, m, -CHAr-) ppm. 
IR νmax: 3393, 3032, 2957, 2361, 2341, 1734, 1508, 1456, 1349, 1244, 1184, 1155, 
1029 cm
-1
 
MS m/z: 523[M+H]
+
, 545 [M+Na]
+
 
HRMS (TOF ESI+): calculated for C27H26N2O723Na1S1 545.1358, found 545.1374 
 
5.2.12. Synthesis of benzyl ester of 2-(4-(benzyloxycarbonylamino)- 
isothiazolidin-3-on-S,S-dioxid-2-yl) propionic acid (ASK-14)  
 
Reaction scheme 1: 
 
Substance ASK-10 (0.76 g, 0.91 mmol) was weighted into perfectly dry 50 ml two-neck 
round-bottom flask. A magnet was added, both necks were closed with rubber septa and 
argon was let to flow through the system. 10 ml of distilled DCM and 0.5 ml of pyridine 
was added with syringe and started to mix. The reaction mixture was subsequently 
cooled down on -80 °C in an acetone bath cooled with immersion cooler. Then 2.5 ekv. 
of bromine (2.29 ml of 1M solution in DCM, 2.29 mmol) was added with syringe 
slowly for 60 minutes. After bromine was added, the reaction mixture was lifted 
from an acetone bath to slowly heat back on room temperature. After 2 hours 10 ml 
of 10mM solution of Na2S2O3 was added, organic phase was separated in separating 
funnel and washed 3× with 20 ml of 15% m/m solution of NaHSO4, 1× with 40 ml 
of s.s. of NaCl. The organic phase was dried using Na2SO4 and the solvent was 
evaporated (47, 48, 49). 
We obtained ASK-12 as a mixture of non- and mono-oxidized form and we continued 
with oxidation in next step to obtain dioxide form without product separation. 
 
Description: orange-brown oily substance 
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Yield: 0.707 g, 93.1 % 
Rf (EtOAc/Hexane = 1/2): 0.40 
 
Reaction scheme 2: 
 
Substance ASK-12 (0.69 g, 1.7 mmol) was weighted in 50 ml round-bottom flask and 
dissolved in 10 ml of distilled DCM. While it was mixing, 2.2 ekv. of mCPBA 
(3.65 mmol, 0.82 g (77%)) was added. It dissolved. The flask was closed and 
the reaction was left to run for 24 hours at r.t. There appeared white precipitate 
at the end of this period. The solvent was evaporated at temperature not exceeeding 
40 °C. The white solid residue was dissolved in 20 ml of EtOAc and transferred into 
separating funnel. Organic phase was washed 2× with 20 ml of s.s of NaHCO3, 3× with 
15 ml of 10% m/V solution of citric acid and 1× with 20 ml of s.s. of NaCl. Organic 
phase was dried with Na2SO4 and then the solvent was evaporated (47, 48, 49). 
The product was purified using column „flash“ chromatography with mobile phase 
EtOAc/Hexane = 1/2. 
 
Description: light yellow oily substance 
Yield: 0.695 g, 94 % 
Rf (EtOAc/Hexane = 2/3): 0.46 
1
H NMR (300MHz, CDCl3): δ = 1.77 (3H, d, J = 7.5 Hz, -CH3), 3.51 (1H, dd, J = 
10.2 Hz, 1.8 Hz, -CH2-S-), 4.76-4.83 (1H, m, -CH-), 4.88-4.95 (1H, m, -CH-), 5.15 (2H, 
s, -CH2-O-), 5.20 (2H, s, -CH2-O-), 5.62 (1H, d, J = 3.6 Hz, -NH-), 7.35-7.38 (10H, m, 
-CHAr-) ppm. 
IR νmax: 3368, 3033, 2955, 2361, 2341, 1759, 1725, 1710, 1518, 1456, 1344, 1267, 
1160, 1103, 1047 cm
-1
 
MS m/z: 447 [M+H]
+
, 469 [M+Na]
+
 
HRMS (TOF ESI+): calculated for C21H22N2O723Na1S1 469.1045, found 469.1058 
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5.2.13. Synthesis of 2-(4-amino-isothiazolidin-3-on-S,S-dioxid-2-yl)- 
3-fenyl propionic acid (ASK-15) 
 
Reaction scheme: 
 
Substance ASK-13 (0.18 g, 0.34 mmol) was dissolved in 15 ml of EtOH abs. and 
transferred into two-neck round-bottom flask. The apparatus for catalytic hydrogenation 
(Figure 33) was prepared. At first, the air was evacuated with water pump for 5 minutes 
(until no more bubbles appeared). Then the system was filled with argon and 
the catalyst was added, 10% m/m of Pd/C (10%) under argon atmosphere. The system 
was evacuated again (untill no more bubbles appeared) and then carefully filled 
with hydrogen. The reaction mixture was kept mixing under hydrogen atmosphere 
for 24 hours. Then 5 ml of glacial acetic acid was added into flask to dissolve our 
compound which precipitated. The catalyst was filtrated off with teflon filter. 
The filtrate was evaporated on rotary evaporator to obtain our final product, which was 
dried 24 hours in a vacuum exsicator over NaOH at room temperature (47, 51). 
 
Description: white crystallic substance with slightly yellowish tint 
Yield: 0.101 g, 99 % 
Rf (CH3CN/MeOH/H2O = 3/1/1): 0.71 
Tm: 120.8 °C 
1
H NMR (300MHz, DMSO-d6): δ = 3.17-3.29 (1H, m, -CH2Phe-), 3.56 -3.45 (2H, m, 
-CH2Phe-, -CH-CO-) 4.01-4.11 (2H, m, -CH2-SO2-), 4.62-4.67 (1H, m, -CHPhe-), 7.19-
7.29 (5H, m, -CHAr-) ppm. 
IR νmax: 3447, 2953, 2361, 2342, 1734, 1617, 1361, 1269, 1163 cm
-1
 
MS m/z: 299 [M+H]
+ 
HRMS (TOF ESI+): calculated for C12H15N2O5S 299.0702, found 299.0711 
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Figure 33: Catalytic hydrogenation apparatus. The apparatus is simple and consists 
of magnetic stirrer and above placed two-neck round-bottom flask. One neck is closed 
with rubber septum and there is flow control adapter with glass stopcock placed 
in second neck. The steps of this reaction procedure are made as numbers goes: 
dissolving the sample in EtOH abs. (1), evacuation of air (2), filling the apparatus 
with argon (3), addition of catalyst Pd/C (4), again evacuation (5) and filling 
the apparatus with hydrogen (6). 
 
5.2.14.  Synthesis of 2-(4-amino-isothiazolidin-3-on-S,S-dioxid-2-yl)  
propionic acid (ASK-16) 
 
Reaction scheme: 
 
Substance ASK-14 (0.4 g, 0.89 mmol) was dissolved in 15 ml of EtOH abs. and 
transferred into two-neck round-bottom flask. The apparatus for catalytic hydrogenation 
was prepared. At first, the air was evacuated with water pump for 5 minutes (until no 
more bubbles appeared). Then the system was filled with argon and the catalyst was 
added, 10% m/m of Pd/C (10%) under argon atmosphere. The system was evacuated 
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again (untill no more bubbles appeared) and then carefully filled with hydrogen. 
The reaction mixture was kept mixing under hydrogen atmosphere for 24 hours. Then 
5 ml of glacial acetic acid was added into flask to dissolve our compound which 
precipitated. The catalyst was filtrated off with teflon filter. The filtrate was evaporated 
on rotary evaporator to obtain our final product, which was dried 24 hours in a vacuum 
exsicator over NaOH at room temperature (47, 51). 
 
Description: white crystallic substance 
Yield: 0.191 g, 96 % 
Rf (CH3CN/MeOH/H2O = 3/1/1): 0.53 
Tm: 121.3 °C 
1
H NMR (300MHz, DMSO-d6): δ = 1.48 (3H, d, J = 7.2 Hz, -CH3Ala), 3.50 (1H, dd, 
J = 12.0 Hz, 3.6 Hz, -CH2-), 4.11-4.20 (2H, m, -CH2-, -CH-CO-), 4.57 (1H, q, J = 
7.2 Hz, -CHαAla-) ppm. 
IR νmax: 2951, 2361, 1734, 1617, 1458, 1354, 1265, 1165, 1048, 1008 cm
-1
 
MS m/z: 223 [M+H]
+
, 245 [M+Na]
+ 
HRMS (TOF ESI+): calculated for C6H11N2O5S 223.0389, found 223.0390 
 
5.2.15.  Synthesis of N,N´-diCbz-D-cystinyl-di-D-aspartyl-dibenzyl ester 
(ASK-18) 
 
Reaction scheme: 
 
Substance ASK-8 was prepared once more (see procedure 5.2.8). It was weighted 
(0.4 g, 0.79 mmol) into 50 ml round-bottom flask, dissolved in 10 ml of DMF and 
placed on an ice bath. Then 2 ekv. of p-toluenesulfonate salt of D-Asp(OBn)2 (0.765 g, 
1.57 mmol), 6 ekv. of NMM (0.52 ml, 4.7 mmol), 2.4 ekv. of HOBt monohydrate 
(0.289 g, 1.89 mmol) and 2.6 ekv. of EDC (0.393 g, 2.04 mmol) were carefully added 
into cooled reaction mixture. The argon was bubbled in and reaction mixture stirred 
for 24 hours at room temperature. The solvent was evaporated on rotary evaporator, 
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yellowish oily residue was dissolved in 20 ml of EtOAc and transferred into separating 
funnel. The organic phase was washed 3× with 20 ml of 0.1M solution of HCl, acid 
water phases were re-extracted 2× with 10 ml of EtOAc. United organic fractions were 
washed 3× with 20 ml of s.s. of NaHCO3 and 1x with 40 ml of s.s. of NaCl. Organic 
phase was dried with Na2SO4, the drying agent filtered and the solvent evaporated 
to yield crude product (46, 47). 
The product was purified using column „flash“ chromatography with mobile phase 
EtOAc/Hexane = 1/1. 
 
Description: white amorphous looking substance 
Yield: 0.674 g, 78 % 
Rf (EtOAc/Hexane = 1/1): 0.63 
Tm: 80.7 °C 
1
H NMR (300MHz, CDCl3): δ = 2.76-3.08 (4H, m, -S-CH2Cys-, -CH2Asp-), 4.86-5.24 
(8H, m, 3× -CH2- (2× Bn + 1× Cbz), -CHCys-, -CHAsp-), 5.76 (1H, d, J = 9.3 Hz, 
-NH-COO-), 7.25-7.40 (15H, m, -CHAr-), 8.24 (1H, d, J = 7.5, -CO-NH-) ppm. 
IR νmax: 3431, 2366, 2345, 1646, 1263, 1044 cm
-1
 
MS m/z: 1099 [M+H]
+
, 1121 [M+Na]
+ 
HRMS (TOF ESI+): calculated for C58H59N4O14S2 1099.3469, found 1099.3470 
 
5.2.16. Synthesis of N,N´-diCbz-D-cystinyl-di-β-alanyl-benzyl ester 
(ASK-19) 
 
Reaction scheme: 
 
We used substance ASK-8 (see procedure 5.2.8). This substance (0.6 g, 1.18 mmol) was 
weighted into 50 ml round-bottom flask and it was dissolved in 10 ml of DMF and 
placed on an ice bath. Into cooled reaction mixture 2 ekv. of p-toluenesulfonate salt 
of β-AlaOBn (0.83 g, 2.36 mmol), 6 ekv. of NMM (0.78 ml, 7.1 mmol), 2.4 ekv. 
of HOBt monohydrate (0.43 g, 2.83 mmol) and 2.6 ekv. of EDC (0.59 g, 3.1 mmol) 
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were carefully added. The argon was bubbled in and reaction mixture stirred 
for 24 hours at room temperature. The solvent was evaporated on rotary evaporator, 
yellowish oily residue was dissolved in 20 ml of EtOAc and transferred into separating 
funnel. The organic phase was washed 3× with 20 ml of 0.1M solution of HCl, acid 
water phases were re-extracted 2× with 10 ml of EtOAc. United organic fractions were 
washed 3× with 20 ml of s.s. of NaHCO3 and 1× with 40 ml of s.s. of NaCl. Organic 
phase was dried with Na2SO4, the drying agent filtered and the solvent evaporated 
to yield crude product (46, 47). 
There was no need to purificate the product, the starting compounds reacted completely 
and the analysis of the product detected no impurities. 
 
Description: white crystallic substance with slightly yellowish tint 
Yield: 0.896 g, 91.5 % 
Rf (DCM/MeOH = 4/1): 0.91 
Tm: 122.7 °C 
1
H NMR (300MHz, CDCl3): δ = 6.59 (2H, td, J = 3.9 Hz, 2.4 Hz, -CH2-COO-), 2.90 
(2H, d, J = 5.7 Hz, -CH2-S-), 3.46-3.61 (2H, m, -CH2-NHCO-), 4.84-4.91 (1H, m, 
-CH-), 5.10 (2H, d, J = 1.2 Hz, -CH2Cbz-), 5.17 (2H, d, J = 1.5 Hz, -CH2Bn-), 5.82 (1H, 
d, J = 9.0 Hz, -NH-Cbz), 7.30-7.37 (10H, m, -CHAr-), 7.73 (1H, s, should be t , -CO-
NH-) ppm. 
IR νmax: 3310, 3090, 3033, 2952, 2365, 2345, 1735, 1690, 1654, 1560, 1534, 1458, 
1387, 1311, 1269, 1229, 1173, 1072, 1040 cm
-1
 
MS m/z: 831 [M+H]
+
, 853 [M+Na]
+ 
HRMS (TOF ESI+): calculated for C42H47N4O10S2 831.2734 found 831.2697 
 
5.2.17. Synthesis of dibenzyl ester of 2-(4-(benzyloxycarbonylamino)- 
isothiazolidin-3-on-S,S-dioxid-2-yl) succinic acid (ASK-22)  
 
Reaction scheme 1: 
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Substance ASK-18 (0.67 g, 0.61 mmol) was weighted into perfectly dry 50 ml two-neck 
round-bottom flask. A magnet was added, both necks were closed with rubber septa and 
argon was let to flow through the system. 10 ml of distilled DCM and 0.5 ml of pyridine 
was added with syringe and started to mix. The reaction mixture was subsequently 
cooled down on -80 °C in an acetone bath cooled with immersion cooler. Then 2.5 ekv. 
of bromine (1.53 ml of 1M solution in DCM, 1.53 mmol) was added with syringe 
slowly for 60 minutes. After bromine was added, the reaction mixture was lifted from 
an acetone bath to slowly heat back on room temperature. After 2 hours 10 ml of 10mM 
solution of Na2S2O3 was added, organic phase was separated in separating funnel and 
washed 3× with 20 ml of 15% m/m solution of NaHSO4 and 1× with 40 ml of s.s. of 
NaCl. The organic phase was dried using Na2SO4 and the solvent was evaporated (47, 
48, 49). 
We obtained ASK-20 as a mixture of non- and mono-oxidized form and we continued 
with oxidation in next step to obtain dioxide form without product separation. 
 
Description: yellow-brown oily substance 
Yield: 0.43 g, 63.9 % 
Rf (EtOAc/Hexane = 1/1): 0.27 
 
Reaction scheme 2: 
 
Substance ASK-20 (0.43 g, 0.78 mmol) was weighted in 50 ml round-bottom flask and 
dissolved in 10 ml of distilled DCM. While it was mixing, 2.2 ekv. of mCPBA 
(1.72 mmol, 0.39 g (77%)) was added. It dissolved. The flask was closed and 
the reaction was left to run for 24 hours at r.t. There appeared white precipitate 
at the end of this period. The solvent was evaporated at temperature not exceeding 
40 °C. The white solid residue was dissolved in 20 ml of EtOAc and transferred 
into separating funnel. Organic phase was washed 2× with 20 ml of s.s of NaHCO3, 3× 
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with 15 ml of 10% m/V solution of citric acid and 1× with 20 ml of s.s. of NaCl. 
Organic phase was dried with Na2SO4 and then the solvent was evaporated (47, 48, 49). 
The product was purified using column „flash“ chromatography with mobile phase 
EtOAc/Hexane = 1/2. 
 
Description: slightly yellow oily substance 
Yield: 0.287 g, 63.4 % 
Rf (EtOAc/Hexane = 1/1): 0.54 
1
H NMR (300MHz, CDCl3): δ = 3.07-3.15 (1H, m, -CH2Asp-), 3.34-3.46 (2H, m, 
-CH2Asp-, -CH2-S-), 4.06-4.16 (1H, m, -CH2-S-), 4.81-4.94 (1H, m, -CH-), 5.10-5.32 
(7H, m, -CHAsp-, -CH2Cbz-, 2× –CH2Bn-), 5.48-5.50 (1H, d, J = 4.5 Hz, -NH-), 7.33-7.37 
(15H, m, -CHAr-) ppm. 
IR νmax: 3378, 3034, 2957, 1741, 1521, 1456, 1348, 1245, 1176, 1044 cm
-1
 
MS m/z: 581 [M+H]
+
, 603 [M+Na]
+ 
HRMS (TOF ESI+): calculated for C29H29N2O9S 581.1594, found 581.1622 
 
5.2.18. Synthesis of benzyl ester of 3-(4-(benzyloxycarbonylamino)- 
isothiazolidin-3-on-S,S-dioxid-2-yl) propionic acid (ASK-23) 
 
Reaction scheme 1: 
 
Substance ASK-19 (0.896 g, 1.1 mmol) was weighted into perfectly dry 50 ml two-neck 
round-bottom flask. A magnet was added, both necks were closed with rubber septa and 
argon was let to flow through the system. 10 ml of distilled DCM and 0.5 ml of pyridine 
was added with syringe and started to mix. The reaction mixture was subsequently 
cooled down on -80 °C in an acetone bath cooled with immersion cooler. Then 2.5 ekv. 
of bromine (2.7 ml of 1M solution in DCM, 2.7 mmol) was added with syringe slowly 
for 60 minutes. After bromine was added, the reaction mixture was lifted 
from an acetone bath to slowly heat back on room temperature. After 2 hours 10 ml 
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of 10mM solution of Na2S2O3 was added, organic phase was separated in separating 
funnel and washed 3× with 20 ml of 15% m/m solution of NaHSO4 and 1× with 40 ml 
of s.s. of NaCl. The organic phase was dried using Na2SO4 and the solvent was 
evaporated (47, 48, 49). 
We obtained ASK-21 as a mixture of non- and mono-oxidized form and we continued 
with oxidation in next step to obtain dioxide form without product separation. 
 
Description: dark yellow oily substance 
Yield: 0.904 g, 98.9 % 
Rf: (EtOAc/Hexane = 1/1): 0.40 
 
Reaction scheme 2: 
 
Substance ASK-21 (0.9 g, 2.2 mmol) was weighted in 50 ml round-bottom flask and 
dissolved in 10 ml of distilled DCM. While it was mixing, 2.2 ekv. of mCPBA 
(4.8 mmol, 1.08 g (77%)) was added. It dissolved. The flask was closed and the reaction 
was left to run for 24 hours at r.t. There appeared white precipitate at the end of this 
period. The solvent was evaporated at temperature not exceeding 40 °C. The white solid 
residue was dissolved in 20 ml of EtOAc and transferred into separating funnel. Organic 
phase was washed 2× with 20 ml of s.s of NaHCO3, 3× with 15 ml of 10% m/V solution 
of citric acid and 1× with 20 ml of s.s. of NaCl. Organic phase was dried with Na2SO4 
and then the solvent was evaporated (47, 48, 49). 
The product was purified using column „flash“ chromatography with mobile phase 
DCM/MeOH = 50/1. 
 
Description: light yellow oily substance 
Yield: 0.428 g, 44.0 % 
Rf (EtOAc/Hexane = 1/1): 0.52 
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1
H NMR (300MHz, CDCl3): δ = 2.80 (2H, t, J = 5.6 Hz, -CαH2Ala- ), 3.59 (1H, dd, J = 
9.6 Hz, 1.5 Hz, -CH2-S-), 3.87-4.04 (3H, m, -CβH2Ala-, -CH2-S-), 4.70-4.88 (1H, m, 
-CH-), 5.13 (4H, s, -CH2Cbz-, -CH2Bn-), 5.84 (1H, d, J = 5.6 Hz, -NH-), 7.36 (10H, d, J = 
1.8 Hz, -CHAr-) ppm. 
IR νmax: 3364, 3033, 2360, 1732, 1520, 1456, 1342, 1249, 1184, 1153, 1042 cm
-1
 
MS m/z: 447 [M+H]
+
, 469 [M+Na]
+ 
HRMS (TOF ESI+): calculated for C21H23N2O7S 447.1226, found 447.1213 
 
5.2.19. Synthesis of 2-(4-amino-isothiazolidin-3-on-S,S-dioxid-2-yl) 
succinic acid (ASK-24) 
 
Reaction scheme: 
 
Substance ASK-22 (0.2 g, 0.34 mmol) was dissolved in 15 ml of glacial acetic acid and 
transferred into two-neck round-bottom flask. The apparatus for catalytic hydrogenation 
was prepared. The air was evacuated with water pump for 5 minutes (until no new 
bubbles appeared). Then the system was filled with argon and the catalyst was added, 
10% m/m of Pd/C (10%). The system was evacuated again (untill no new bubbles 
appeared) and then carefully filled with hydrogen. The reaction mixture was kept 
mixing under hydrogen atmosphere for 24 hours. Then the catalyst was filtrated off 
with teflon filter. The filtrate was evaporated on rotary evaporator to obtain our final 
product, which was triturated few times with EtOEt and then dried for 24 hours 
in a vacuum exsicator over NaOH at room temperature (47, 51). 
 
Description: white crystallic substance 
Yield: 0.09g, 99 % 
Rf (CH3CN/MeOH/H2O = 3/1/1): 0.45 
Tm: 124.0 °C 
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1
H NMR (300MHz, DMSO-d6): δ = 2.59 (1H, dd, J = 6.6 Hz, 4.2 Hz, -CH2Asp-), 2.70 
(1H, dd, J = 6.6 Hz, 9.3 Hz, -CH2Asp-), 3.40-3.48 (1H, m, -CH2-S-), 4.05-4.10 (1H, m, 
-CH2-S-), 4.12-4.20 (2H, m, 2× -CH-) ppm. 
IR νmax: 3422, 3237, 2994, 2365, 2345, 1744, 1604, 1388, 1329, 1266, 1149, 1114, 
1020 cm
-1
 
MS m/z: 265 [M-H]ˉ 
HRMS (TOF ESI+): calculated for C7H9N2O7S 265.0130, found 265.0131 
 
5.2.20.  Synthesis of 3-(4-amino-isothiazolidin-3-on-S,S-dioxid-2-yl) 
propionic acid (ASK-25) 
 
Reaction scheme: 
 
Substance ASK-23 (0.31 g, 0.70 mmol) was dissolved in 15 ml of glacial acetic acid 
and transferred into two-neck round-bottom flask. The apparatus for catalytic 
hydrogenation was prepared. The air was evacuated with water pump for 5 minutes 
(until no new bubbles appeared). Then the system was filled with argon and the catalyst 
was added, 10% m/m of Pd/C (10%). The system was evacuated again (untill no new 
bubbles appeared) and then carefully filled with hydrogen. The reaction mixture was 
kept mixing under hydrogen atmosphere for 24 hours. Then the catalyst was filtrated off 
with teflon filter. The filtrate was evaporated on rotary evaporator to obtain our final 
product, which was triturated few times with EtOEt and then dried for 24 hours in a 
vacuum exsicator over NaOH at room temperature (47, 51). 
 
Description: white crystallic substance 
Yield: 0.147 g, 94.8 % 
Rf: (CH3CN/MeOH/H2O = 3/1/1): 0.60 
Tm: 92.4 °C 
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1
H NMR (300MHz, DMSO-d6): δ = 2.55 (2H, we cannot observe the shape, hidden 
behind DMSO peak, -CαH2(Ala)-), 3.43-3.50 (2H, m, -CH2-S-), 3.62-3.70 (2H, m, 
-CβH2(Ala)-), 4.10-4.15 (1H, m, -CH-) ppm. 
IR νmax: 2955, 2362, 1734, 1340, 1160 cm
-1
 
MS m/z: 223 [M+H]
+
  
HRMS (TOF ESI+): calculated for C6H11N2O5S 223.0389, found 223.0389  
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5.3. Biological testing 
 
The synthetised inhibitors were tested for IC50 and for residual activity (RA) 
of DDlB from E. coli. The residual activity was measured in two ways. In coupled 
enzyme ATPase assay (PK/LDH assay) where created ADP is measured and 
in malachite green assay where Pi released is measured. 
The coupled enzyme ATPase assay (seee Figure 34) is based on the conversion 
of phosphoenolpyruvate (PEP) to pyruvate by pyruvate kinase (PK) coupled 
to the conversion of pyruvate to lactate by lactate dehydrogenase (LDH). The latter step 
requires NADH which is oxidized to NAD
+
. NADH absorbs strongly at 340 nm but 
NAD
+
 does not, enabling the ultilization of NADH to be followed by monitoring 
absorbance at 340 nm. The decrease in absorbance at 340 nm can be converted 
into ATPase activity where 1 molecule of NADH oxidized to NAD
+
 corresponds 
to the production of 1 molecule of ADP by the ATPase (in our case DDl) (52). 
 
 
 
 
 
Figure 34: Principle of the coupled PK/LDH ATPase assay. 
 
Assay with malachite green (see Figure 35) is based on quantification of the green 
complex formed between malachite green, molybdate and Pi (created by ATPase 
activity). The rapid color formation from the reaction can be measured on a 
spectrophotometer (600 - 660 nm) (53). 
 
 
 
 
 
 
Figure 35: Principle of the malachite green assay. MG/AM - Malachite 
Green/Ammonium Molybdate dye. 
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*with 5mM D-Ala as a substrate 
**with 2mM D-Ala as a substrate, compound C = 1mM 
***with 700µM D-Ala as a substrate, compound C = 500µM 
 For positive control was used D-cycloserine 
RA (PK/LDH assay) = 71%, RA (Malachite green assay) = 30% 
 
Table 2: Results of biological tests of synthetised compounds 
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The results of biological assays (see Table 2) on DDl we obtained are quite 
promising, although for the IC50 are one order of magnitude weaker than the ones 
of D-cycloserine. The most active compound is the simplest one (ASK-6), which means 
that we did not succeed to optimize inhibitory activity by adding additional aminoacid 
residues. In fact only 2 of the compounds had IC50 one order of magnitude lower than 
D-cycloserine (IC50 of D-cycloserine is around 300 μM, (39)). ASK-24 and ASK-25 
were not active at all in tested concentrations. We may conclude that these molecules 
are either too big for DDl active site cavity although AutoDock predicts they could 
accomodate in it. The alternative possibility is that sulfoxide does not match phosphate-
binding site, so the observed lower affinity may be due to lack of interactions 
with phosphate binding site (different possition was predicted by AutoDock in ASK-25 
molecule). 
Interesting fact is that a positive control (D-cycloserine) inhibits DDl in 1mM 
concentration with RA of DDl = 71%. This means that the compounds ASK-6 and 
ASK-16 seems to be in the same magnitude of potency as D-cycloserine, which is 
promissing. 
The experimental data suggest that isothiazolidinone-based dipeptide analogues 
do mimic D-Ala-D-Ala dipeptide and consequently they do inhibit DDl. Docking 
prediction data did predict an alternative binding mode of ASK-25, which explains its 
lower inhibitory activity, but failed to predict binding energies in a quantitative manner. 
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6. Conclusion 
 
In this work we managed to design new type of DDl inhibitors and succeeded 
in synthesizing 5 final compounds with isothiazolidinone core which were later 
evaluated in biological assays to determine their DDl inhibitory potency. Prepared 
potential inhibitors were tested on isolated DDl enzyme. The results of assay were not 
succesfull but at least it gave us some positive promising ideas. We have found out that 
amino acid residues on isothiazolidinone core in most of the cases do not improve 
the activity of the inhibitor. The most active compound was the simplest one we have 
prepared. Hovewer the most active compounds in biological assays were comparable 
with D-cycloserine in residual activity. 
The biggest contribution of our work can be seen in research and discovery 
of new potentially effective DDl inhibitors. Compound ASK-5, the best active 
compound of all seems to be a good target of subsequent research and testing. As well 
we have found reproducible and reliable methods of synthetising new compounds 
with isothiazolidinone scaffold which could be profitable in further development of new 
DDl inhibitors or other drugs. 
Question is wheather this original molecule, obtained from molecular modeling 
and efficient against the isolated enzyme can also be efficient in the whole cell assays 
where MIC are determined. This justifies further studies and testing of the respective 
enzyme and inhibitor. As well there are lot of possibilities to modulate presented 
scaffold to obtain adequate inhibition activity, bioavailability and other appropriate 
pharmacokinetic properties. In my opinion, development of potentially useful 
compounds in this series is possible. 
 
 
 
 
 
 
 
 
SUCHANOVÁ KLÁRA                                                                                     DIPLOMOVÁ PRÁCE    
78 
7. Abbreviations 
 
ADP adenosine diphosphate 
Ala alanine 
Alr alanine racemase 
AM ammonium molybdate 
Ar aromatic or argon 
ASK initials of supervisor and diploma thesis worker 
ATP adenosine-5'-triphosphate 
Bn benzyl 
Boc tert-butyloxycarbonil 
Cbz benzyloxycarbonyl 
Cys cystine 
DA  diamino acid 
DAP meso-diaminopimelic acid 
DCC N,N'-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DDl D-Ala-D-Ala ligase 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
ESI electrospray ionization 
EtOAc  ethyl acetate 
EtOEt diethyl ether 
EtOH ethanol 
EUR-INTAFAR Inhibition of New TArgets for Fighting Antibiotic Resistance 
FAB fast atom bombardment 
FID free induction decay  
HOBt N-hydroxybenzotriazole 
IC50 half maximal inhibitory concentration 
IR infrared spectroscopy 
Ki inhibition constant 
LDH lactate dehydrogenase 
LPS lipopolysaccharide 
Lys lysine 
mCPBA m-chloroperoxybenzoic acid 
MeOH methanol 
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MG malachite green 
MIC minimum inhibitory concentration 
MP mobile phase 
MS mass spectrometry 
MW microwave 
NAD
+
 nicotinamide adenine dinucleotide 
NADH nicotinamide adenine dinucleotide (reduced form) 
NAG (GlcNac) N-acetylglucosamine 
NAM (MurNAc) N-acetylmuramic acid 
NMM N-methylmorpholine 
NMR nuclear magnetic resonance 
PBPs penicillin-binding proteins  
Pd/C palladium on activated charcoal 
PEP phosphoenolpyruvate 
Ph phenyl 
Phe phenylalanine 
Pi inorganic phosphate 
PK pyruvate kinase 
ppm parts per million 
PTFE polytetrafluoroethylene 
pTOS p-toluenesulfonate 
Py pyridine 
r.t. room temperature 
RA residual activity 
Rf retention factor 
s.s. saturated solution 
tBu tert-butyl 
TFA trifluoroacetic acid 
TLC thin layer chromatography 
TMS tetramethylsilane 
UDP uridine diphosphate 
VRE vancomycin resistant Enterococci 
VRSA vancomycin-resistant Staphylococcus aureus 
WHO World Health Organization 
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